JPH0140009B2 - - Google Patents
Info
- Publication number
- JPH0140009B2 JPH0140009B2 JP54162879A JP16287979A JPH0140009B2 JP H0140009 B2 JPH0140009 B2 JP H0140009B2 JP 54162879 A JP54162879 A JP 54162879A JP 16287979 A JP16287979 A JP 16287979A JP H0140009 B2 JPH0140009 B2 JP H0140009B2
- Authority
- JP
- Japan
- Prior art keywords
- acetaminophen
- composition
- compound
- methyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 264
- 229960005489 paracetamol Drugs 0.000 claims description 118
- 239000000203 mixture Substances 0.000 claims description 45
- -1 2,6-dichlorophenyl Chemical group 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 20
- 208000002193 Pain Diseases 0.000 claims description 16
- 230000036407 pain Effects 0.000 claims description 15
- CMWTZPSULFXXJA-UHFFFAOYSA-N 2-(6-methoxy-2-naphthalenyl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 claims description 3
- RJMIEHBSYVWVIN-UHFFFAOYSA-N indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003424 phenylacetic acid Drugs 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000012747 synergistic agent Substances 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- XCKQRGVGTNNDKF-UHFFFAOYSA-N 2-[2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC=CC=C2C1=CC1=CC=C(S(C)=O)C=C1 XCKQRGVGTNNDKF-UHFFFAOYSA-N 0.000 claims 1
- QWTVQAFQEOKLRY-UHFFFAOYSA-N acetic acid;2,6-dichloro-n-phenylaniline Chemical compound CC(O)=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 QWTVQAFQEOKLRY-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 44
- 239000011780 sodium chloride Substances 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 29
- 230000000202 analgesic effect Effects 0.000 description 29
- 239000003814 drug Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- 229920002472 Starch Polymers 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 23
- 239000004615 ingredient Substances 0.000 description 23
- 235000019698 starch Nutrition 0.000 description 23
- 239000003826 tablet Substances 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 239000008107 starch Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 17
- 229960004187 indoprofen Drugs 0.000 description 16
- 229960000991 ketoprofen Drugs 0.000 description 16
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 15
- 235000013539 calcium stearate Nutrition 0.000 description 15
- 239000008116 calcium stearate Substances 0.000 description 15
- 239000007903 gelatin capsule Substances 0.000 description 15
- 239000008187 granular material Substances 0.000 description 14
- 230000003187 abdominal effect Effects 0.000 description 13
- 230000037396 body weight Effects 0.000 description 13
- ZEHGKSPCAMLJDC-UHFFFAOYSA-M acetylcholine bromide Chemical compound [Br-].CC(=O)OCC[N+](C)(C)C ZEHGKSPCAMLJDC-UHFFFAOYSA-M 0.000 description 12
- 230000008602 contraction Effects 0.000 description 12
- 229960001259 diclofenac Drugs 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000007900 aqueous suspension Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 229960002009 naproxen Drugs 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 9
- 210000004303 peritoneum Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000012937 correction Methods 0.000 description 8
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000002260 anti-inflammatory agent Substances 0.000 description 7
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 7
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000012057 packaged powder Substances 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- 235000012431 wafers Nutrition 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 229960001419 fenoprofen Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 5
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 229960001193 diclofenac sodium Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RDJGLLICXDHJDY-UHFFFAOYSA-N fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 2
- 229960003940 naproxen sodium Drugs 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- MFSJSVNVUDQHLV-QHUNOZLZSA-N (2S)-2-(3-benzoylphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1.OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MFSJSVNVUDQHLV-QHUNOZLZSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- WVKIYGXHDKTNFO-UHFFFAOYSA-M sodium;2-(3-phenoxyphenyl)propanoate Chemical compound [Na+].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 WVKIYGXHDKTNFO-UHFFFAOYSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
æ¬çºæã¯é®çå€ã補é ããããã®æ¹åãããæ¹
æ³ããã³çµæç©ã«é¢ããã å»è¬ã®é·ãæžå¿µã«ãªã€ãŠããäž»ç®çã®äžã€ã¯ã
çã¿ã®è»œæžã§ããã軜æžã¯ãæãäžè¬çã«ã¯ãæ
èŠã®æç¥ãæžå°ãããçã¿ã®ãããå€ãå¢å€§ãã
ãç¶æ ãã€ããåºãé®çå€ã®æäžã«ãã€ãŠè¿œæ±ã
ããŠããã æ®ã©å šãŠã®ãå¹åã®ããé®çå€ã¯ãçã¿ã®è»œæž
以å€ã®åäœçšããã²ãèµ·ããåäœçšã®ããã€ãã®
ãã®ã¯ãèè žé害ãåæ°ã䟿ç§ããã³ååã§ã
ããæŽã«é倧ãªå¯äœçšã®ãã¡ã§ããŸãé®çå€ã«ã
ã°ãã°èŠããããã®ã¯ãåŒåžæ鬱ã§ãããåŸã€
ãŠãäž»ã«é®çå€ã䜿çšããå Žåã¯ãäž»ããå¹æ
ïŒé®çïŒä»¥å€ã®èæ ®ã®å¿ èŠããããæå°ã®å¯äœçš
ãã䌎ããæ倧ã®é®çå¹æãæãããçã¿ã軜æž
ããããã®è¬å€ãæ±ããããŠãããäžè¬ã«ãå¹å
ã®ããé®çå€ã¯é倧ãªå¯äœçšã䌎ããäžæ¹ãå°ã
ããå¯äœçšãæããªãè¬å€ãŸãã¯å šãå¯äœçšãæ
ããªãè¬å€ã¯ãäžè¬ã«ãé®çå€ãšããŠå¹æãäœã
ã®ã§ãåäžã®ååŠç©è³ªã§ãããã®èŠæ±ãæºããã
ãšã¯å°é£ã§ããã åŸã€ãŠãããã«ãã€ãŠè¬å€ã®å šéãæžããããš
ãã§ããäžã€å ãã®å¯äœçšããæããæãã¯å šã
å¯äœçšãæããæ倧ã®é®çå¹æãäžãããããªæ¯
çã§äœ¿çšããããšãã§ãããïŒçš®ãŸãã¯å€çš®ã®è¬
å€ã®çµã¿åãããç¶ããŠæ¢ç©¶ãããŠãããïŒæ¹ãŸ
ãã¯äž¡æ¹ã®çµã¿åãæåãçã¿ã軜æžããæ§è³ªã
æããããšãå ¬ç¥ã§ãããããããããã®ãã®ã®
æ§è³ªãäœå±€åã«ãå¢å€§ãããå Žåã¯ããã®çµã¿å
ãã®æ£å³ã®å¹æãæ®éãçžä¹äœçšããšåŒã¶ã ã¢ã»ãã¢ããããšã³ïŒïœâã¢ã»ãã¢ããããšã
ãŒã«ïŒã¯æå¹ã§å®å šãªææ害å容åšæ§ãæããé®
çå€ãšããŠç¥ãããŠãããããããæãäºäŸã§
ã¯ãçã¿ãæå¹ã«æããã«ã¯é«æçšéãçšããªã
ãã°ãªããªãã次ã®è¬å€ã¯ãããã§ãããã
è¡šããããé®çç¹æ§ãæããïŒ ïŒ¡ ïŒâãïŒïŒïŒïŒâãžã¯ããããšãã«ïŒã¢ããã
ãã³ãŒã³é ¢é žã¯ããžã¯ãããšããã¯ããšããå±
åã§æççå€ãšããŠäœ¿çšãåŸãããšãå ¬ç¥ã§ã
ãããŸããããã¯é®çç¹æ§ãå€å°æããããã®
ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒïŒºïŒâïŒâãã«ãªãâïŒâã¡ãã«âïŒâ
ïœãïŒâïŒã¡ãã«ã¹ã«ãã€ãã«ïŒããšãã«ãâã¡
ãã¬ã³ïœâ1Hâã€ã³ãã³âïŒâé ¢é žã¯ãããµãª
ã³ããã¯ããšããå±åã§ãæççå€ãšããŠäœ¿çš
ãåŸãããšãå ¬ç¥ã§ããããŸãããã®ãã®ã¯é®
çç¹æ§ãæããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒâïŒïŒâãããšããªã«ã«ã«ããã«ïŒâãã
ããªã³é žã¯ããããšã³ããŠããšã³ããšããå±å
ã§ãæççå€ãšããŠã®äœ¿çšãå ¬ç¥ã§ããããŸ
ãããã®ãã®ã¯ãé®çç¹æ§ãå€å°æããããã®
ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒâã¡ããã·âαâã¡ãã«âïŒâããã¿ã¬ã³
é ¢é žã¯ããããããã»ã³ããšããå±åã§ãæç
çå€ãé®çå€ãŸãã¯è§£ç±å€ãšããŠã®äœ¿çšãå ¬ç¥
ã§ããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  ïœâãã³ãŸã€ã«ãããã¢ãããé žã¯ããã±ã
ããããšã³ããšããå±åã§ãæççå€ãšããŠã®
䜿çšãå ¬ç¥ã§ããããŸãããã®ãã®ã¯é®çç¹æ§
ããå€å°æããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒâïŒïŒïŒïŒâãžãããâïŒâãªããœâ2H
âã€ãœã€ã³ããŒã«âïŒâã€ã«ïŒâαâã¡ãã«ã
ã³ãŒã³é ¢é žã¯ããã€ã³ãããããšã³ããšããå±
åã§ãæççå€ãšããŠããã³é®çå€ãšããŠã®äœ¿
çšãå ¬ç¥ã§ããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  αâã¡ãã«âïŒâããšããã·ãã³ãŒã³é ¢é ž
ã¯ããããšãããããšã³ããšããå±åã§ãæç
çå€ããã³é®çå€ãšããŠã®äœ¿çšãå ¬ç¥ã§ããã
ãã®ãã®ã¯äžèšåŒ ã§è¡šããããã ããããªãããã¢ã»ãã¢ããããšãã³ããã³è¬
å€ïŒ¡ä¹è³ïŒ§ã®äœããäžã€ã®çµã¿åããé®çç¹æ§ã«
åãŒãå¹æã¯ãåºé¡è ãã®ç 究以åã«ã¯ç¥ãããŠ
ããªãã€ãã æ¬çºæã¯ãé®çå€ã補é ããããã®ãè¬å€ïŒ¡ä¹
è³ïŒ§ã®äœããäžã€ãŸãã¯ãã®å¡©ã®é®çç¹æ§ãŸãã¯
ææ害å容åšç¹æ§ã®çžä¹äœçšãç¹å®ã®æ¯çã§ã¢ã»
ãã¢ããããšã³ãšäžç·ã«æäžããããšã«ãã€ãŠåŸ
ããããšããçºèŠã«ããå¯èœãšãªã€ããæ¹åãã
ãæ¹æ³ã«é¢ãããçã¿ã®æå¶ã«ãã®çµã¿åããçš
ããå¹æã¯ãæåã®å¯æçãªå¹æããåã«çèµ·ã
ããšæãããããããäºæ³ä»¥äžã«é¥ãã«å€§ããã ãã®æ°èŠã§äžã€äºæ³ä»¥äžã®åªããé®çç¹æ§ã¯ã
(1)ã¢ã»ãã¢ããããšã³ããã³(2)äžèšã®ååç©ïŒ¡ä¹
è³ïŒ§ã®ïŒã€ããŸãã¯æ²»çåŠçã«åã容ããããã
ããã®ãã®ã®å¡©ã®ãåæãŸãã¯é次çµå£æäžã«ã
ã€ãŠéæãåŸãããã®æ²»çåŠçã«åã容ãããã
å¡©ã¯ãé©åœãªææ©ãŸãã¯ç¡æ©ã®å¡©åºããåŸããã
ãã®ã§ããã奜ãŸããå¡©ã¯ã«ãªãŠã å¡©çãå«ãŸã
ãã æ°èŠãªçµã¿åãã®ææ害å容åšç¹æ§ãçŸåºãã
æå¹æ§ã¯ãCollierãã®ãBrit.J.Pharmacol.
Chemotherap.32ïŒ295â310ïŒ1968ïŒãæã ãããŠ
ã¹ã©ã€ãžã³ã°ãã¹ãïŒããã¿ã®ããã¡è©ŠéšïŒããš
åŒã°ããã¢ã»ãã«ã³ãªã³ãããã€ãè ¹éšåçž®åæ
ã§æ®ã«ããèŠãããããã®è©Šéšã§ã¯ãããŠã¹ã«è©Š
éšè¬å€ã®çµã¿åããæçšããç¶ãåŸã¢ã»ãã«ã³ãª
ã³ãããã€ããè ¹èãéããŠæ³šå ¥ããè ¹éšåçž®å
å¿ãŸãã¯è ¹éšåçž®åå¿ã®åŠšå®³ã芳枬ããç §æ»æšæº
ã®æäœãšæ¯èŒããã æŽã«ç¹å®çã«ã¯ãCollierããã³å ±åç 究è ã«
ããèšèŒãããåŠãã«å®è³ªäžè¡ãªãæäœã«æŒããŠ
ã¯ã18ã24ïœã®éãã®æé£ãããŠããªãçœããã¿
ã«ãéžå®ããåºå®æçšéã®ïŒã€ã®è©Šéšè¬å€ããå
åºå®æçšéã«å¯Ÿãçš®ã ã®æçšéã®ç¬¬ïŒã®è©Šéšè¬å€
ãšçµã¿åããŠæçšãããããããã®ãã®ãã (a) çµã¿åããŠäœ¿çšããåãæçšéã®ç¬¬äžã®è©Šéš
è¬å€ãäœã第äºã®è¬å€ã®ãããã«ççé£å¡©æ°Žã
䜿çšã (b) çµã¿åããŠäœ¿çšããæçšéã®ç¬¬äºã®è©Šéšè¬
å€ãäœã第äžã®è¬å€ã®ãããã«ççé£å¡©æ°Žã䜿
çšãããã³ (c) è¬å€ãå«ãŸãªãççé£å¡©æ°Žã®ç §æ»æšæºãæçš
ãããåç©ãšæ¯èŒãããåè¬å€ã¯ãã°ãã°ãã«
䜿çšããå Žåã¯ãã¢ã»ãã«ã³ãªã³ãããã€ãè ¹
éšå瞮詊éšã§ã¯è©Šéšã®æçšæ°Žæºã§ã¯äžæŽ»æ§ã§ã
ãããšãå€ã€ãã è©Šéšãè¡ãªãéã¯ãè¬å€ãæãããã®ãæããª
ããã®ãäž¡æ¹ãè©Šéšçµæç©ããã³ç §æ»æšæºçµæç©
ããè©Šéšã®ããŠã¹ã«çµå£çã«æäžãããçŽ30ååŸ
ããŠã¹ã«ã¢ã»ãã«ã³ãªã³ãããã€ããè ¹èãéã
ãŠæ³šå ¥ãè ¹éšåçž®åå¿ãæ¯èŒããïŒå¿ èŠã«å¿ããŠ
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£ããïŒãçµæã¯åŠš
害ã®ïŒ ãšããŠè¡šèšãããã åºå®æçšéãçšããŠèŠ³æž¬ãããè ¹éšåçž®ã®åŠšå®³
ã®ïŒ ãïŒïŒ ãŸãã¯ãã以äžã®æã¯ãåçµã¿åãæ
çšæ°ŽæºãçšããŠèŠ³æž¬ããã劚害ã®ïŒ ããèªç¶ã®æ»
亡çã«å¯ŸããAbbottã®åŒãçšããŠãåºå®æçšé
ã®è¬å€ãçšããŠèŠ³æž¬ããã劚害ã®ïŒ ã«é¢ããŠè£æ£
ãè¡ãªã€ãã åæ§ã«ççé£å¡©æ°Žã®ç §æ»æšæºçŸ€ã®ã¢ã»ãã«ã³ãª
ã³ãããã€ãã«å¯Ÿããåå¿ã95ïŒ ãŸãã¯ãã以äž
ã®æã¯ãED50枬å®ã§äœ¿çšããçš®ã ã®åæçšæ°Žæº
ãçšããŠèŠ³æž¬ãããåå¿ããåæ§ã«ãèªç¶ã®æ»äº¡
çã«å¯ŸããAbbottã®åŒãçšããŠè£æ£ãããED50
ããã³95ïŒ ä¿¡é Œéçã¯Finneyã®ãããããåæ
æ³ïŒFinneyïŒD.J.1964ïŒProbit AnalysisïŒç¬¬ïŒ
çãUniversity PressïŒCambridgeïŒã«åŸã€ãŠèš
ç®ãããããäžããããæ¯èŒã«å¯ŸããED50ã¯ã
å šãŠãå¹³è¡çŸè±¡ã®è©Šéšã«åŸãå ±éã®åŸããçšããŠ
èšç®ãããå šãŠã®å¯Ÿã«ãªã€ãæè¬åå¿æ²ç·ã¯å¹³è¡
ã§ããããšãå€ã€ãã ååç© ïŒ¡ äžèšã®æé ãçšããŠãïŒâãïŒïŒïŒïŒâãžã¯ã
ãããšãã«ïŒã¢ãããâãã³ãŒã³é ¢é žååç©ïŒã
ã®åŸæã ããžã¯ãããšããã¯ååç©ããšåŒã¶ïŒã®
é®çç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«ããçžä¹äœçšã
äŸç€ºãåŸããç¹æ§ã¯ãžã¯ãããšããã¯ã®ãããªãŠ
ã å¡©ãçšããŠäŸç€ºããããããã ãã«éå®ããã
ãã®ã§ã¯ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第ïœããã³ïœè¡šã«ç€ºãåŠãçš®ã ã®
æçšéã®ãžã¯ãããšããã¯ãããªãŠã ããã³çç
é£å¡©æ°ŽãããããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³
25mgïŒKgãŸãã¯50mgïŒKgããçµå£çã«æçšãã
ããè©Šéšè¬å€ããã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæ
çšæ°Žæºã¯ãçµå£ã§äžããŸãçµå£ã§è¡šç€ºãããåæ
çšæ°Žæºã«å¯Ÿã20å¹ã®ããŠã¹ãçšãããç §æ»æšæºãš
ããŠã¯ãåæ§ã®æ°ã®ããŠã¹ã«(a)ã¢ã»ãã¢ããããš
ã³ïŒ25mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸ
ãã¯ã¢ã»ãã¢ããããšã³ïŒ50mgïŒKgïŒããã³çç
é£å¡©æ°ŽïŒïŒmlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒ
KgïŒïŒåæçšåãæçšãããããžã¯ãããšããã¯
ãããªãŠã ã¯æ°Žæº¶æ¶²ãšããŠæäžãããã¢ã»ãã¢ã
ãããšã³ã¯æ°Žæ§æžæ¿æ¶²ãšããŠæäžããã ãžã¯ãããšããã¯ãããªãŠã ãæäžããŠ30ååŸ
ïŒã¢ã»ãã¢ããããšãã³ãæäžããŠ15ååŸïŒãããŠ
ã¹ã«ã¢ã»ãã«ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹è
ãéããŠæ³šå ¥ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ã
ããED50ã®å€ã¯ã芳枬ãããå€ãããåã«è°è«
ããé©åãªè£æ£ãããã«é©çšããŠã決å®ããã ããªãã¡ãäžèšåŒ ïŒïŒ¡ïŒïŒ®ïŒ100âïŒ¡ïŒ ããã§ãã¯ãã¢ã»ãã¢ããããšã³ãšéã¹ãã
ã€ãç³»æççå€ã®çµåãã«ã€ããŠãåé¡ã«ãªã€ãŠ
ããå¹æãããªãã¡ãçã¿ã®æå¶ã®åºŠåã瀺ãå®
éã«èŠ³å¯ãããå¹æã®å€§ããã§ããïŒïŒ¡ã¯ã¢ã»ã
ã¢ããããšã³ã®ã¿ã®æäžã«ããå¹æã®å€§ããã§ã
ãïŒãããŠïŒ®ã¯åæ§ã«ã¢ã»ãã¢ããããšã³ãšéã¹
ããã€ãç³»æççå€ã®çµåãã«ã€ããŠãéã¹ãã
ã€ãç³»æççå€ãå¯äžããå¹æã®å€§ããã§ããã ã§è¡šããããã¢ãããã®åŒãçšãããããå¹æ
ãå€æããã°ãå¹æãšå®éã«èŠ³å¯ãããå¹æ
ãšãäžèšã¢ãããã®åŒã«ãã€ãŠãå¹æããªãã¡
çµåãæäžã«ãããéã¹ããã€ãç³»æççå€ã®å¹
æã®å€§ãããæ±ãŸãããšã«ãªããããæ ããã®å¹
æã®å€§ããããéã¹ããã€ãç³»æççå€ã®ã¿ã
æäžããå Žåã®å¹æãšæ¯èŒããŠå¹æã®æ¹ã倧ã
ããã°ãçžå°å¹æã®ååšãæãããšãªãã 以äžã®ç¬¬ïŒâïœè¡šä»¥éã®å®æœäŸã§ã¯ããã®ã
ããããããïŒã»ããã®å®éšãè¡ã€ãã ïŒ ççé£å¡©æ°Žã®ã¿ã«ããåŠç ïŒ ã¢ã»ãã¢ããããšã³ã®åºå®æäžéãšççé£å¡©
æ°Žãšã«ããåŠçã ïŒ éã¹ããã€ãç³»æççå€ã®å¹Ÿã€ãã®æäžéãš
ççé£å¡©æ°Žãšã®åçµåãã«ããåŠçãããã³ ïŒ éã¹ããã€ãç³»æççå€ã®å¹Ÿã€ãã®æäžéãš
äžèšïŒïŒãšåãåºå®æäžéã®ã¢ã»ãã¢ããããš
ã³ãšã®åçµåãã«ããåŠçã äžèšïŒïŒã§åŸãããçµæ(C)ã«ã€ããŠãã¢ããã
ã®åŒãçšããŠäžèšïŒïŒã§åŸãããçµæ(A)ãè£æ£
ãããŸãåæ§ã«äžèšïŒïŒã§åŸãããçµæã«ã€ããŠ
ã¢ãããã®åŒãçšããŠäžèšïŒïŒã§åŸãããçµæã
è£æ£ããããããçµåãæäžã«ãããéã¹ããã€
ãç³»æççå€ã®å¹æãšåç¬æäžã«ãããéã¹ãã
ã€ãç³»æççå€ã®å¹æãæ±ããã第âïœè¡šä»¥é
ã®å šãŠã®è¡šäžã«ã¯ããããã®è£æ£ããå¹æã®å€§ã
ããã«ãã³æžãã§ç€ºããã 第âïœè¡šã®çµæãäŸã«ãšã€ãŠèª¬æããã°ããž
ã¯ãããšããã¯åç¬æäžã®å Žåã®ED50ã®å€ïŒã«
ãã³å ã®å€ïŒããããçµåãæäžã®å Žåã®ãžã¯ã
ããšããã¯ã®å¯äžã«ããED50ã®å€ïŒã«ãã³å ã®
å€ïŒã95ïŒ ä¿¡é Œéçã«ãããŠæããã«å°ããã
ããçµåãæäžã«ããçžå°å¹æã®ååšããããã çµæã¯ç¬¬ïœããã³ïœè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
æ³ããã³çµæç©ã«é¢ããã å»è¬ã®é·ãæžå¿µã«ãªã€ãŠããäž»ç®çã®äžã€ã¯ã
çã¿ã®è»œæžã§ããã軜æžã¯ãæãäžè¬çã«ã¯ãæ
èŠã®æç¥ãæžå°ãããçã¿ã®ãããå€ãå¢å€§ãã
ãç¶æ ãã€ããåºãé®çå€ã®æäžã«ãã€ãŠè¿œæ±ã
ããŠããã æ®ã©å šãŠã®ãå¹åã®ããé®çå€ã¯ãçã¿ã®è»œæž
以å€ã®åäœçšããã²ãèµ·ããåäœçšã®ããã€ãã®
ãã®ã¯ãèè žé害ãåæ°ã䟿ç§ããã³ååã§ã
ããæŽã«é倧ãªå¯äœçšã®ãã¡ã§ããŸãé®çå€ã«ã
ã°ãã°èŠããããã®ã¯ãåŒåžæ鬱ã§ãããåŸã€
ãŠãäž»ã«é®çå€ã䜿çšããå Žåã¯ãäž»ããå¹æ
ïŒé®çïŒä»¥å€ã®èæ ®ã®å¿ èŠããããæå°ã®å¯äœçš
ãã䌎ããæ倧ã®é®çå¹æãæãããçã¿ã軜æž
ããããã®è¬å€ãæ±ããããŠãããäžè¬ã«ãå¹å
ã®ããé®çå€ã¯é倧ãªå¯äœçšã䌎ããäžæ¹ãå°ã
ããå¯äœçšãæããªãè¬å€ãŸãã¯å šãå¯äœçšãæ
ããªãè¬å€ã¯ãäžè¬ã«ãé®çå€ãšããŠå¹æãäœã
ã®ã§ãåäžã®ååŠç©è³ªã§ãããã®èŠæ±ãæºããã
ãšã¯å°é£ã§ããã åŸã€ãŠãããã«ãã€ãŠè¬å€ã®å šéãæžããããš
ãã§ããäžã€å ãã®å¯äœçšããæããæãã¯å šã
å¯äœçšãæããæ倧ã®é®çå¹æãäžãããããªæ¯
çã§äœ¿çšããããšãã§ãããïŒçš®ãŸãã¯å€çš®ã®è¬
å€ã®çµã¿åãããç¶ããŠæ¢ç©¶ãããŠãããïŒæ¹ãŸ
ãã¯äž¡æ¹ã®çµã¿åãæåãçã¿ã軜æžããæ§è³ªã
æããããšãå ¬ç¥ã§ãããããããããã®ãã®ã®
æ§è³ªãäœå±€åã«ãå¢å€§ãããå Žåã¯ããã®çµã¿å
ãã®æ£å³ã®å¹æãæ®éãçžä¹äœçšããšåŒã¶ã ã¢ã»ãã¢ããããšã³ïŒïœâã¢ã»ãã¢ããããšã
ãŒã«ïŒã¯æå¹ã§å®å šãªææ害å容åšæ§ãæããé®
çå€ãšããŠç¥ãããŠãããããããæãäºäŸã§
ã¯ãçã¿ãæå¹ã«æããã«ã¯é«æçšéãçšããªã
ãã°ãªããªãã次ã®è¬å€ã¯ãããã§ãããã
è¡šããããé®çç¹æ§ãæããïŒ ïŒ¡ ïŒâãïŒïŒïŒïŒâãžã¯ããããšãã«ïŒã¢ããã
ãã³ãŒã³é ¢é žã¯ããžã¯ãããšããã¯ããšããå±
åã§æççå€ãšããŠäœ¿çšãåŸãããšãå ¬ç¥ã§ã
ãããŸããããã¯é®çç¹æ§ãå€å°æããããã®
ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒïŒºïŒâïŒâãã«ãªãâïŒâã¡ãã«âïŒâ
ïœãïŒâïŒã¡ãã«ã¹ã«ãã€ãã«ïŒããšãã«ãâã¡
ãã¬ã³ïœâ1Hâã€ã³ãã³âïŒâé ¢é žã¯ãããµãª
ã³ããã¯ããšããå±åã§ãæççå€ãšããŠäœ¿çš
ãåŸãããšãå ¬ç¥ã§ããããŸãããã®ãã®ã¯é®
çç¹æ§ãæããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒâïŒïŒâãããšããªã«ã«ã«ããã«ïŒâãã
ããªã³é žã¯ããããšã³ããŠããšã³ããšããå±å
ã§ãæççå€ãšããŠã®äœ¿çšãå ¬ç¥ã§ããããŸ
ãããã®ãã®ã¯ãé®çç¹æ§ãå€å°æããããã®
ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒâã¡ããã·âαâã¡ãã«âïŒâããã¿ã¬ã³
é ¢é žã¯ããããããã»ã³ããšããå±åã§ãæç
çå€ãé®çå€ãŸãã¯è§£ç±å€ãšããŠã®äœ¿çšãå ¬ç¥
ã§ããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  ïœâãã³ãŸã€ã«ãããã¢ãããé žã¯ããã±ã
ããããšã³ããšããå±åã§ãæççå€ãšããŠã®
䜿çšãå ¬ç¥ã§ããããŸãããã®ãã®ã¯é®çç¹æ§
ããå€å°æããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  ïŒâïŒïŒïŒïŒâãžãããâïŒâãªããœâ2H
âã€ãœã€ã³ããŒã«âïŒâã€ã«ïŒâαâã¡ãã«ã
ã³ãŒã³é ¢é žã¯ããã€ã³ãããããšã³ããšããå±
åã§ãæççå€ãšããŠããã³é®çå€ãšããŠã®äœ¿
çšãå ¬ç¥ã§ããããã®ãã®ã¯äžèšåŒ ã§è¡šããããã  αâã¡ãã«âïŒâããšããã·ãã³ãŒã³é ¢é ž
ã¯ããããšãããããšã³ããšããå±åã§ãæç
çå€ããã³é®çå€ãšããŠã®äœ¿çšãå ¬ç¥ã§ããã
ãã®ãã®ã¯äžèšåŒ ã§è¡šããããã ããããªãããã¢ã»ãã¢ããããšãã³ããã³è¬
å€ïŒ¡ä¹è³ïŒ§ã®äœããäžã€ã®çµã¿åããé®çç¹æ§ã«
åãŒãå¹æã¯ãåºé¡è ãã®ç 究以åã«ã¯ç¥ãããŠ
ããªãã€ãã æ¬çºæã¯ãé®çå€ã補é ããããã®ãè¬å€ïŒ¡ä¹
è³ïŒ§ã®äœããäžã€ãŸãã¯ãã®å¡©ã®é®çç¹æ§ãŸãã¯
ææ害å容åšç¹æ§ã®çžä¹äœçšãç¹å®ã®æ¯çã§ã¢ã»
ãã¢ããããšã³ãšäžç·ã«æäžããããšã«ãã€ãŠåŸ
ããããšããçºèŠã«ããå¯èœãšãªã€ããæ¹åãã
ãæ¹æ³ã«é¢ãããçã¿ã®æå¶ã«ãã®çµã¿åããçš
ããå¹æã¯ãæåã®å¯æçãªå¹æããåã«çèµ·ã
ããšæãããããããäºæ³ä»¥äžã«é¥ãã«å€§ããã ãã®æ°èŠã§äžã€äºæ³ä»¥äžã®åªããé®çç¹æ§ã¯ã
(1)ã¢ã»ãã¢ããããšã³ããã³(2)äžèšã®ååç©ïŒ¡ä¹
è³ïŒ§ã®ïŒã€ããŸãã¯æ²»çåŠçã«åã容ããããã
ããã®ãã®ã®å¡©ã®ãåæãŸãã¯é次çµå£æäžã«ã
ã€ãŠéæãåŸãããã®æ²»çåŠçã«åã容ãããã
å¡©ã¯ãé©åœãªææ©ãŸãã¯ç¡æ©ã®å¡©åºããåŸããã
ãã®ã§ããã奜ãŸããå¡©ã¯ã«ãªãŠã å¡©çãå«ãŸã
ãã æ°èŠãªçµã¿åãã®ææ害å容åšç¹æ§ãçŸåºãã
æå¹æ§ã¯ãCollierãã®ãBrit.J.Pharmacol.
Chemotherap.32ïŒ295â310ïŒ1968ïŒãæã ãããŠ
ã¹ã©ã€ãžã³ã°ãã¹ãïŒããã¿ã®ããã¡è©ŠéšïŒããš
åŒã°ããã¢ã»ãã«ã³ãªã³ãããã€ãè ¹éšåçž®åæ
ã§æ®ã«ããèŠãããããã®è©Šéšã§ã¯ãããŠã¹ã«è©Š
éšè¬å€ã®çµã¿åããæçšããç¶ãåŸã¢ã»ãã«ã³ãª
ã³ãããã€ããè ¹èãéããŠæ³šå ¥ããè ¹éšåçž®å
å¿ãŸãã¯è ¹éšåçž®åå¿ã®åŠšå®³ã芳枬ããç §æ»æšæº
ã®æäœãšæ¯èŒããã æŽã«ç¹å®çã«ã¯ãCollierããã³å ±åç 究è ã«
ããèšèŒãããåŠãã«å®è³ªäžè¡ãªãæäœã«æŒããŠ
ã¯ã18ã24ïœã®éãã®æé£ãããŠããªãçœããã¿
ã«ãéžå®ããåºå®æçšéã®ïŒã€ã®è©Šéšè¬å€ããå
åºå®æçšéã«å¯Ÿãçš®ã ã®æçšéã®ç¬¬ïŒã®è©Šéšè¬å€
ãšçµã¿åããŠæçšãããããããã®ãã®ãã (a) çµã¿åããŠäœ¿çšããåãæçšéã®ç¬¬äžã®è©Šéš
è¬å€ãäœã第äºã®è¬å€ã®ãããã«ççé£å¡©æ°Žã
䜿çšã (b) çµã¿åããŠäœ¿çšããæçšéã®ç¬¬äºã®è©Šéšè¬
å€ãäœã第äžã®è¬å€ã®ãããã«ççé£å¡©æ°Žã䜿
çšãããã³ (c) è¬å€ãå«ãŸãªãççé£å¡©æ°Žã®ç §æ»æšæºãæçš
ãããåç©ãšæ¯èŒãããåè¬å€ã¯ãã°ãã°ãã«
䜿çšããå Žåã¯ãã¢ã»ãã«ã³ãªã³ãããã€ãè ¹
éšå瞮詊éšã§ã¯è©Šéšã®æçšæ°Žæºã§ã¯äžæŽ»æ§ã§ã
ãããšãå€ã€ãã è©Šéšãè¡ãªãéã¯ãè¬å€ãæãããã®ãæããª
ããã®ãäž¡æ¹ãè©Šéšçµæç©ããã³ç §æ»æšæºçµæç©
ããè©Šéšã®ããŠã¹ã«çµå£çã«æäžãããçŽ30ååŸ
ããŠã¹ã«ã¢ã»ãã«ã³ãªã³ãããã€ããè ¹èãéã
ãŠæ³šå ¥ãè ¹éšåçž®åå¿ãæ¯èŒããïŒå¿ èŠã«å¿ããŠ
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£ããïŒãçµæã¯åŠš
害ã®ïŒ ãšããŠè¡šèšãããã åºå®æçšéãçšããŠèŠ³æž¬ãããè ¹éšåçž®ã®åŠšå®³
ã®ïŒ ãïŒïŒ ãŸãã¯ãã以äžã®æã¯ãåçµã¿åãæ
çšæ°ŽæºãçšããŠèŠ³æž¬ããã劚害ã®ïŒ ããèªç¶ã®æ»
亡çã«å¯ŸããAbbottã®åŒãçšããŠãåºå®æçšé
ã®è¬å€ãçšããŠèŠ³æž¬ããã劚害ã®ïŒ ã«é¢ããŠè£æ£
ãè¡ãªã€ãã åæ§ã«ççé£å¡©æ°Žã®ç §æ»æšæºçŸ€ã®ã¢ã»ãã«ã³ãª
ã³ãããã€ãã«å¯Ÿããåå¿ã95ïŒ ãŸãã¯ãã以äž
ã®æã¯ãED50枬å®ã§äœ¿çšããçš®ã ã®åæçšæ°Žæº
ãçšããŠèŠ³æž¬ãããåå¿ããåæ§ã«ãèªç¶ã®æ»äº¡
çã«å¯ŸããAbbottã®åŒãçšããŠè£æ£ãããED50
ããã³95ïŒ ä¿¡é Œéçã¯Finneyã®ãããããåæ
æ³ïŒFinneyïŒD.J.1964ïŒProbit AnalysisïŒç¬¬ïŒ
çãUniversity PressïŒCambridgeïŒã«åŸã€ãŠèš
ç®ãããããäžããããæ¯èŒã«å¯ŸããED50ã¯ã
å šãŠãå¹³è¡çŸè±¡ã®è©Šéšã«åŸãå ±éã®åŸããçšããŠ
èšç®ãããå šãŠã®å¯Ÿã«ãªã€ãæè¬åå¿æ²ç·ã¯å¹³è¡
ã§ããããšãå€ã€ãã ååç© ïŒ¡ äžèšã®æé ãçšããŠãïŒâãïŒïŒïŒïŒâãžã¯ã
ãããšãã«ïŒã¢ãããâãã³ãŒã³é ¢é žååç©ïŒã
ã®åŸæã ããžã¯ãããšããã¯ååç©ããšåŒã¶ïŒã®
é®çç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«ããçžä¹äœçšã
äŸç€ºãåŸããç¹æ§ã¯ãžã¯ãããšããã¯ã®ãããªãŠ
ã å¡©ãçšããŠäŸç€ºããããããã ãã«éå®ããã
ãã®ã§ã¯ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第ïœããã³ïœè¡šã«ç€ºãåŠãçš®ã ã®
æçšéã®ãžã¯ãããšããã¯ãããªãŠã ããã³çç
é£å¡©æ°ŽãããããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³
25mgïŒKgãŸãã¯50mgïŒKgããçµå£çã«æçšãã
ããè©Šéšè¬å€ããã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæ
çšæ°Žæºã¯ãçµå£ã§äžããŸãçµå£ã§è¡šç€ºãããåæ
çšæ°Žæºã«å¯Ÿã20å¹ã®ããŠã¹ãçšãããç §æ»æšæºãš
ããŠã¯ãåæ§ã®æ°ã®ããŠã¹ã«(a)ã¢ã»ãã¢ããããš
ã³ïŒ25mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸ
ãã¯ã¢ã»ãã¢ããããšã³ïŒ50mgïŒKgïŒããã³çç
é£å¡©æ°ŽïŒïŒmlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒ
KgïŒïŒåæçšåãæçšãããããžã¯ãããšããã¯
ãããªãŠã ã¯æ°Žæº¶æ¶²ãšããŠæäžãããã¢ã»ãã¢ã
ãããšã³ã¯æ°Žæ§æžæ¿æ¶²ãšããŠæäžããã ãžã¯ãããšããã¯ãããªãŠã ãæäžããŠ30ååŸ
ïŒã¢ã»ãã¢ããããšãã³ãæäžããŠ15ååŸïŒãããŠ
ã¹ã«ã¢ã»ãã«ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹è
ãéããŠæ³šå ¥ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ã
ããED50ã®å€ã¯ã芳枬ãããå€ãããåã«è°è«
ããé©åãªè£æ£ãããã«é©çšããŠã決å®ããã ããªãã¡ãäžèšåŒ ïŒïŒ¡ïŒïŒ®ïŒ100âïŒ¡ïŒ ããã§ãã¯ãã¢ã»ãã¢ããããšã³ãšéã¹ãã
ã€ãç³»æççå€ã®çµåãã«ã€ããŠãåé¡ã«ãªã€ãŠ
ããå¹æãããªãã¡ãçã¿ã®æå¶ã®åºŠåã瀺ãå®
éã«èŠ³å¯ãããå¹æã®å€§ããã§ããïŒïŒ¡ã¯ã¢ã»ã
ã¢ããããšã³ã®ã¿ã®æäžã«ããå¹æã®å€§ããã§ã
ãïŒãããŠïŒ®ã¯åæ§ã«ã¢ã»ãã¢ããããšã³ãšéã¹
ããã€ãç³»æççå€ã®çµåãã«ã€ããŠãéã¹ãã
ã€ãç³»æççå€ãå¯äžããå¹æã®å€§ããã§ããã ã§è¡šããããã¢ãããã®åŒãçšãããããå¹æ
ãå€æããã°ãå¹æãšå®éã«èŠ³å¯ãããå¹æ
ãšãäžèšã¢ãããã®åŒã«ãã€ãŠãå¹æããªãã¡
çµåãæäžã«ãããéã¹ããã€ãç³»æççå€ã®å¹
æã®å€§ãããæ±ãŸãããšã«ãªããããæ ããã®å¹
æã®å€§ããããéã¹ããã€ãç³»æççå€ã®ã¿ã
æäžããå Žåã®å¹æãšæ¯èŒããŠå¹æã®æ¹ã倧ã
ããã°ãçžå°å¹æã®ååšãæãããšãªãã 以äžã®ç¬¬ïŒâïœè¡šä»¥éã®å®æœäŸã§ã¯ããã®ã
ããããããïŒã»ããã®å®éšãè¡ã€ãã ïŒ ççé£å¡©æ°Žã®ã¿ã«ããåŠç ïŒ ã¢ã»ãã¢ããããšã³ã®åºå®æäžéãšççé£å¡©
æ°Žãšã«ããåŠçã ïŒ éã¹ããã€ãç³»æççå€ã®å¹Ÿã€ãã®æäžéãš
ççé£å¡©æ°Žãšã®åçµåãã«ããåŠçãããã³ ïŒ éã¹ããã€ãç³»æççå€ã®å¹Ÿã€ãã®æäžéãš
äžèšïŒïŒãšåãåºå®æäžéã®ã¢ã»ãã¢ããããš
ã³ãšã®åçµåãã«ããåŠçã äžèšïŒïŒã§åŸãããçµæ(C)ã«ã€ããŠãã¢ããã
ã®åŒãçšããŠäžèšïŒïŒã§åŸãããçµæ(A)ãè£æ£
ãããŸãåæ§ã«äžèšïŒïŒã§åŸãããçµæã«ã€ããŠ
ã¢ãããã®åŒãçšããŠäžèšïŒïŒã§åŸãããçµæã
è£æ£ããããããçµåãæäžã«ãããéã¹ããã€
ãç³»æççå€ã®å¹æãšåç¬æäžã«ãããéã¹ãã
ã€ãç³»æççå€ã®å¹æãæ±ããã第âïœè¡šä»¥é
ã®å šãŠã®è¡šäžã«ã¯ããããã®è£æ£ããå¹æã®å€§ã
ããã«ãã³æžãã§ç€ºããã 第âïœè¡šã®çµæãäŸã«ãšã€ãŠèª¬æããã°ããž
ã¯ãããšããã¯åç¬æäžã®å Žåã®ED50ã®å€ïŒã«
ãã³å ã®å€ïŒããããçµåãæäžã®å Žåã®ãžã¯ã
ããšããã¯ã®å¯äžã«ããED50ã®å€ïŒã«ãã³å ã®
å€ïŒã95ïŒ ä¿¡é Œéçã«ãããŠæããã«å°ããã
ããçµåãæäžã«ããçžå°å¹æã®ååšããããã çµæã¯ç¬¬ïœããã³ïœè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ãè¡šã
ä»ã®å®éšããã¢ã»ãã¢ããããšã³ã50mgïŒKgæ°Ž
æºã§ãã䜿çšããªãç¹ä»¥å€ã¯å ã®å®æœäŸã«èšèŒã
ãæ¹æ³ã§è¡ãªã€ããçµæã第â²è¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgãã䜿çšãããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
æºã§ãã䜿çšããªãç¹ä»¥å€ã¯å ã®å®æœäŸã«èšèŒã
ãæ¹æ³ã§è¡ãªã€ããçµæã第â²è¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgãã䜿çšãããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ãè¡šã
äžèšã®çµæã¯ããžã¯ãããšããã¯ååç©ã®é®ç
ãŸãã¯ææ害å容åšç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«
ããçžä¹äœçšãäŸç€ºããã æ¬çºæã¯ãå³ã¡é®çå€ã補é ããæ¹æ³ã¯ãçã¿
ã«èŠãã被æ€äœå³ã¡ããããã³ä»ã®æž©è¡åç©ã«ã
ååç©ïŒ¡ä¹è³ïŒ§ã®ïŒã€ããã³ã¢ã»ãã¢ããããšã³
ããææ害å容åšå¹æãæããã«ååãªéã ãçµ
å£çã«æäžããããšããæãã該詊å€ã¯åæã«ãŸ
ãã¯é ã ã«æäžããããšãã§ããäœãã®è©Šå€ãå
ã«æäžããŠããããåŸã«æ瀺ããåŠãéã®è©Šå€ã
æäžããããšã«ãã€ãŠãåæåã®å ¬ç¥ã®æ§è³ªãã
ã¯å šãäºæãããªãã€ãè©Šå€çžäºéã®ææ害å容
çžäºäœçšãéããããã掻æ§è©Šå€ã¯ãæ äœç¡ãæ
ãã¯æ äœãšãšãã«æäžããããšãã§ãããæäžã®
äžã€ã®æ¹æ³ã¯ãæçšåäœã®åœ¢ãããçµæç©ãçšã
ãããšã«ãããã®ã§ãããã«ãã䟿å®çãªåææ
äžæ³ãæäŸãããã ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããååç©ïŒ¡ã®å Žåã¯ãçŽ0.08ä¹è³0.47
mgïŒKgã®ãžã¯ãããšããã¯ååç©ãçŽ1.8ä¹è³7.5
mgïŒKgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšããã
ãšãã§ãã奜ãŸããã¯çŽ0.17ä¹è³0.33mgïŒKgã®ãž
ã¯ãããšããã¯ååç©ãçŽ2.1ä¹è³7.1mgïŒKgã®ã¢
ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã
ããšã決å®ãããããããã®éã¯ãããã«é©ãã
æçšéãšããŠè¡šãããšãçŽïŒä¹è³28mgã®ãžã¯ãã
ãšããã¯ååç©ããã³çŽ110ä¹è³450mgã®ã¢ã»ãã¢
ããããšã³ã奜ãŸããã¯çŽ10ä¹è³20mgã®ãžã¯ãã
ãšããã¯ååç©ããã³125ä¹è³425mgã®ã¢ã»ãã¢ã
ãããšã³ãšããç¯å²ã«ãªãã é¡èãªç¹æ§ã¯ãæ¬çºæã®æ°èŠãªè¬å€çµæç©ãçš
ããããšã«ãã€ãŠãæå¹ã«å©çšããããšãã§ã
ããæ¬çºæã®è¬å€çµæç©ã補é ããããã«ã¯ãäž»
äœçšå€ãšããŠã®ååç©ïŒ¡ä¹è³ïŒ§ã®ïŒã€ããã³çžä¹
äœçšå€ãšããŠã®ã¢ã»ãã¢ããããšã³ããçµå£æäž
ã«é©ããè¬åŠçã«å容ã§ããæ äœãšå¯ã«æ··åãã
ããçµå£æçšã®åœ¢ã®çµæç©ã補é ããéã¯ãéåžž
ã®è¬åŠåªäœãªãåŠäœãªããã®ã§ã䜿çšããããšã
ã§ããããã«ã¯äžèšã®ãã®ãå«ãŸããïŒæžæ¿å€ã
ãšãªãã·ã«ããã³æº¶æ¶²ã®åŠãçµå£æ¶²äœèª¿åç©çšãš
ããŠæ°Žãã°ãªã³ãŒã«ãæ²¹ãã¢ã«ã³ãŒã«çã®åŠã液
äœæ äœïŒç²å€ãã«ãã»ã«å€ããã³é å€çšãšããŠã
最æ»å€ããã€ã³ããŒãèšåå€çãšããŠæ©èœããæ
æãå«ããããã³ãã³ãç³ãã«ãªãªã³ãã¹ãã¢ãª
ã³é žã«ã«ã·ãŠã ããšãã«ã»ã«ããŒã¹çã®åŠãåºäœ
æ äœããã®æäžã®å®¹ææ§ã®ãããé å€ããã³ã«ã
ã»ã«å€ã¯æãæå©ãªçµå£æçšåœ¢ã§ããããããã®
çµæç©ã¯äžèšã®ãã³ãã³ãç³ãã«ãªãªã³çã®åŠã
åºäœã®è¬åŠæ äœã䜿çšããŠãããäžè¬ã«ãã¹ãã¢
ãªã³é žã«ã«ã·ãŠã ã®åŠã最æ»å€ãå«ããæäžã®å®¹
æãããã³æçšéã®åäžæ§ã®ããã«äžèšã®è¬åŠçµ
æç©ãæçšåäœã®åœ¢ã«ããã®ãæ®ã«æå©ã§ããã
æ现æžããã³ç¹èš±è«æ±ã®ç¯å²ã«æŒããŠããã§çšã
ãŠãããæçšåäœåœ¢ããªãèªã¯ãåäœã®æçšéãš
ããŠå¥œé©ãªãç©ççã«å¥åã®åäœãæããã®ã§ã
ããååäœã¯ãèŠæ±ãããè¬åŠæ äœãšå ±åããŠæ
ã¿ã®æ²»çåŠçå¹æãçããããã«èšç®ãããäºã
決ããããéã®æŽ»æ§æåãå«æããããã®ãããª
æçšåäœåœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžžè¬ãå
è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéçããã³
ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããååç©ïŒ¡ã®å Ž
åã¯ãäžã€ã®æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãš
ããŠçŽïŒä¹è³28mgã®ïŒâãïŒïŒïŒïŒâãžã¯ããã
ãšãã«ïŒã¢ããããã³ãŒã³é ¢é žååç©ãçŽ110ä¹
è³450mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã
奜ãŸããæçšåäœã¯ïŒååç©ïŒ¡ãçšããå ŽåãïŒ
çŽ125ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«ã
ïŒâãïŒïŒïŒïŒâãžã¯ããããšãã«ïŒã¢ãããã
ã³ãŒã³é ¢é žååç©çŽ10ä¹è³20mgã§ããã ååç© ïŒ¢ äžèšã®æé ãçšããŠãïŒïŒºïŒâïŒâãã«ãªãâ
ïŒâã¡ãã«âïŒâïœïŒïŒâã¡ãã«ã¹ã«ãã€ãã«ïŒ
ããšãã«ãã¡ãã¬ã³ïœâ1Hâã€ã³ãã³âïŒâé ¢
é žååç©ïŒä»¥åŸæã ããµãªã³ããã¯ååç©ããšåŒ
ã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«ããçžä¹
äœçšãäŸç€ºããããšãã§ããããã®æ§è³ªã¯ãµãªã³
ããã¯ïŒé žã®åœ¢ïŒãçšããããšã«ãã€ãŠäŸç€ºãã
ãããããã ãã«éå®ããããã®ã§ã¯ãªãããšã¯
ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第2aããã³ç¬¬2bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ãµãªã³ããã¯ããã³ççé£å¡©æ°Žããã
ããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸã
ã¯50mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ã
ãã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£
ã§äžããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯Ÿã20
å¹ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠã¯ãåæ§ã®
æ°ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒ
KgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸãã¯ã¢ã»ã
ã¢ããããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒ
mlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒïŒåæ
çšåãæçšãããããµãªã³ããã¯ã¯æ°Žæ§æžæ¿å€ãš
ããŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§æžæ¿å€
ãšããŠæäžããã ãµãªã³ããã¯ãæäžããŠ30ååŸïŒã¢ã»ãã¢ãã
ããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«ã³
ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥ãã
è ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€ã¯ã
芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£ãã
ãã«é©çšããŠæ±ºå®ãããçµæã¯ç¬¬2aããã³ç¬¬2b
è¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãŸãã¯ææ害å容åšç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«
ããçžä¹äœçšãäŸç€ºããã æ¬çºæã¯ãå³ã¡é®çå€ã補é ããæ¹æ³ã¯ãçã¿
ã«èŠãã被æ€äœå³ã¡ããããã³ä»ã®æž©è¡åç©ã«ã
ååç©ïŒ¡ä¹è³ïŒ§ã®ïŒã€ããã³ã¢ã»ãã¢ããããšã³
ããææ害å容åšå¹æãæããã«ååãªéã ãçµ
å£çã«æäžããããšããæãã該詊å€ã¯åæã«ãŸ
ãã¯é ã ã«æäžããããšãã§ããäœãã®è©Šå€ãå
ã«æäžããŠããããåŸã«æ瀺ããåŠãéã®è©Šå€ã
æäžããããšã«ãã€ãŠãåæåã®å ¬ç¥ã®æ§è³ªãã
ã¯å šãäºæãããªãã€ãè©Šå€çžäºéã®ææ害å容
çžäºäœçšãéããããã掻æ§è©Šå€ã¯ãæ äœç¡ãæ
ãã¯æ äœãšãšãã«æäžããããšãã§ãããæäžã®
äžã€ã®æ¹æ³ã¯ãæçšåäœã®åœ¢ãããçµæç©ãçšã
ãããšã«ãããã®ã§ãããã«ãã䟿å®çãªåææ
äžæ³ãæäŸãããã ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããååç©ïŒ¡ã®å Žåã¯ãçŽ0.08ä¹è³0.47
mgïŒKgã®ãžã¯ãããšããã¯ååç©ãçŽ1.8ä¹è³7.5
mgïŒKgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšããã
ãšãã§ãã奜ãŸããã¯çŽ0.17ä¹è³0.33mgïŒKgã®ãž
ã¯ãããšããã¯ååç©ãçŽ2.1ä¹è³7.1mgïŒKgã®ã¢
ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã
ããšã決å®ãããããããã®éã¯ãããã«é©ãã
æçšéãšããŠè¡šãããšãçŽïŒä¹è³28mgã®ãžã¯ãã
ãšããã¯ååç©ããã³çŽ110ä¹è³450mgã®ã¢ã»ãã¢
ããããšã³ã奜ãŸããã¯çŽ10ä¹è³20mgã®ãžã¯ãã
ãšããã¯ååç©ããã³125ä¹è³425mgã®ã¢ã»ãã¢ã
ãããšã³ãšããç¯å²ã«ãªãã é¡èãªç¹æ§ã¯ãæ¬çºæã®æ°èŠãªè¬å€çµæç©ãçš
ããããšã«ãã€ãŠãæå¹ã«å©çšããããšãã§ã
ããæ¬çºæã®è¬å€çµæç©ã補é ããããã«ã¯ãäž»
äœçšå€ãšããŠã®ååç©ïŒ¡ä¹è³ïŒ§ã®ïŒã€ããã³çžä¹
äœçšå€ãšããŠã®ã¢ã»ãã¢ããããšã³ããçµå£æäž
ã«é©ããè¬åŠçã«å容ã§ããæ äœãšå¯ã«æ··åãã
ããçµå£æçšã®åœ¢ã®çµæç©ã補é ããéã¯ãéåžž
ã®è¬åŠåªäœãªãåŠäœãªããã®ã§ã䜿çšããããšã
ã§ããããã«ã¯äžèšã®ãã®ãå«ãŸããïŒæžæ¿å€ã
ãšãªãã·ã«ããã³æº¶æ¶²ã®åŠãçµå£æ¶²äœèª¿åç©çšãš
ããŠæ°Žãã°ãªã³ãŒã«ãæ²¹ãã¢ã«ã³ãŒã«çã®åŠã液
äœæ äœïŒç²å€ãã«ãã»ã«å€ããã³é å€çšãšããŠã
最æ»å€ããã€ã³ããŒãèšåå€çãšããŠæ©èœããæ
æãå«ããããã³ãã³ãç³ãã«ãªãªã³ãã¹ãã¢ãª
ã³é žã«ã«ã·ãŠã ããšãã«ã»ã«ããŒã¹çã®åŠãåºäœ
æ äœããã®æäžã®å®¹ææ§ã®ãããé å€ããã³ã«ã
ã»ã«å€ã¯æãæå©ãªçµå£æçšåœ¢ã§ããããããã®
çµæç©ã¯äžèšã®ãã³ãã³ãç³ãã«ãªãªã³çã®åŠã
åºäœã®è¬åŠæ äœã䜿çšããŠãããäžè¬ã«ãã¹ãã¢
ãªã³é žã«ã«ã·ãŠã ã®åŠã最æ»å€ãå«ããæäžã®å®¹
æãããã³æçšéã®åäžæ§ã®ããã«äžèšã®è¬åŠçµ
æç©ãæçšåäœã®åœ¢ã«ããã®ãæ®ã«æå©ã§ããã
æ现æžããã³ç¹èš±è«æ±ã®ç¯å²ã«æŒããŠããã§çšã
ãŠãããæçšåäœåœ¢ããªãèªã¯ãåäœã®æçšéãš
ããŠå¥œé©ãªãç©ççã«å¥åã®åäœãæããã®ã§ã
ããååäœã¯ãèŠæ±ãããè¬åŠæ äœãšå ±åããŠæ
ã¿ã®æ²»çåŠçå¹æãçããããã«èšç®ãããäºã
決ããããéã®æŽ»æ§æåãå«æããããã®ãããª
æçšåäœåœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžžè¬ãå
è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéçããã³
ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããååç©ïŒ¡ã®å Ž
åã¯ãäžã€ã®æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãš
ããŠçŽïŒä¹è³28mgã®ïŒâãïŒïŒïŒïŒâãžã¯ããã
ãšãã«ïŒã¢ããããã³ãŒã³é ¢é žååç©ãçŽ110ä¹
è³450mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã
奜ãŸããæçšåäœã¯ïŒååç©ïŒ¡ãçšããå ŽåãïŒ
çŽ125ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«ã
ïŒâãïŒïŒïŒïŒâãžã¯ããããšãã«ïŒã¢ãããã
ã³ãŒã³é ¢é žååç©çŽ10ä¹è³20mgã§ããã ååç© ïŒ¢ äžèšã®æé ãçšããŠãïŒïŒºïŒâïŒâãã«ãªãâ
ïŒâã¡ãã«âïŒâïœïŒïŒâã¡ãã«ã¹ã«ãã€ãã«ïŒ
ããšãã«ãã¡ãã¬ã³ïœâ1Hâã€ã³ãã³âïŒâé ¢
é žååç©ïŒä»¥åŸæã ããµãªã³ããã¯ååç©ããšåŒ
ã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«ããçžä¹
äœçšãäŸç€ºããããšãã§ããããã®æ§è³ªã¯ãµãªã³
ããã¯ïŒé žã®åœ¢ïŒãçšããããšã«ãã€ãŠäŸç€ºãã
ãããããã ãã«éå®ããããã®ã§ã¯ãªãããšã¯
ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第2aããã³ç¬¬2bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ãµãªã³ããã¯ããã³ççé£å¡©æ°Žããã
ããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸã
ã¯50mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ã
ãã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£
ã§äžããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯Ÿã20
å¹ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠã¯ãåæ§ã®
æ°ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒ
KgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸãã¯ã¢ã»ã
ã¢ããããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒ
mlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒïŒåæ
çšåãæçšãããããµãªã³ããã¯ã¯æ°Žæ§æžæ¿å€ãš
ããŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§æžæ¿å€
ãšããŠæäžããã ãµãªã³ããã¯ãæäžããŠ30ååŸïŒã¢ã»ãã¢ãã
ããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«ã³
ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥ãã
è ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€ã¯ã
芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£ãã
ãã«é©çšããŠæ±ºå®ãããçµæã¯ç¬¬2aããã³ç¬¬2b
è¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ïŒïŒ ãã®åã®åŠšå®³ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒ
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ãè¡šã
ïŒïŒ ãã®åã®åŠšå®³ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒ
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®æçšç¯å²ã
ããäžè¬ã«ãçŽ0.1ä¹è³1.7mgïŒKgã®ãµãªã³ããã¯
ååç©ãçŽ1.0ä¹è³7.5mgïŒKgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜ãŸããã¯ãçŽ
0.17ä¹è³1.5mgã®ãµãªã³ããã¯ååç©ãçŽ1.7ä¹è³
7.1mgïŒKgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšã
åŸããšã決å®ãããããããã®éã¯ãããã«é©ã
ãæçšéãšããŠè¡šãããšãçŽïŒä¹è³100mgã®ãµãª
ã³ããã¯ååç©ããã³çŽ65ä¹è³450mgã®ã¢ã»ãã¢
ããããšã³ã奜ãŸããã¯çŽ10ä¹è³90mgã®ãµãªã³ã
ãã¯ååç©ããã³çŽ100ä¹è³425mgã®ã¢ã»ãã¢ãã
ããšã³ãšããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽïŒä¹è³
100mgã®ãµãªã³ããã¯ååç©ããçŽ65ä¹è³450mgã®
ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã奜ãŸãã
æçšåäœã¯ãçŽ100ä¹è³425mgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«ããµãªã³ããã¯ååç©çŽ10ä¹è³90mgã§
ããã ååç© ïŒ£ äžèšã®æé ãçšããŠãïŒâïŒïŒâãããšããªã«
ã«ã«ããã«ïŒâããããªã³é žååç©ïŒä»¥åŸæã
ãããšã³ããŠãã³ååç©ããšãã¶ïŒã®é®çç¹æ§ã®
ã¢ã»ãã¢ããããšã³ã«ããçžä¹äœçšãäŸç€ºããã
ãšãã§ããããã®æ§è³ªã¯ããšã³ããŠãã³ïŒé žã®
圢ïŒãçšããããšã«ãã€ãŠäŸç€ºãããããããã
ãã«éå®ããããã®ã§ã¯ãªãããšã¯ç解ããã
ãã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第3aããã³ç¬¬3bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ããšã³ããŠãã³ããã³å¡©ãããããŠ15
ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸãã¯50
mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ããã³
ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£ã§äž
ããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯ŸããŠ20å¹
ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠãåæ§ã®æ°ã®
ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒKgïŒã
ãã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸãã¯ã¢ã»ãã¢ãã
ããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒ
KgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒïŒåæçšå
ãæçšããããããšã³ããŠãã³ã¯æ°Žæ§æžæ¿å€ãšã
ãŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§æžæ¿å€ãš
ããŠæäžããã ããšã³ããŠãã³ãæäžããŠ30ååŸïŒã¢ã»ãã¢ã
ãããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«
ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥
ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€
ã¯ã芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£
ãããã«é©çšããŠæ±ºå®ãããçµæã¯ç¬¬3aããã³
第3bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®æçšç¯å²ã
ããäžè¬ã«ãçŽ0.1ä¹è³1.7mgïŒKgã®ãµãªã³ããã¯
ååç©ãçŽ1.0ä¹è³7.5mgïŒKgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜ãŸããã¯ãçŽ
0.17ä¹è³1.5mgã®ãµãªã³ããã¯ååç©ãçŽ1.7ä¹è³
7.1mgïŒKgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšã
åŸããšã決å®ãããããããã®éã¯ãããã«é©ã
ãæçšéãšããŠè¡šãããšãçŽïŒä¹è³100mgã®ãµãª
ã³ããã¯ååç©ããã³çŽ65ä¹è³450mgã®ã¢ã»ãã¢
ããããšã³ã奜ãŸããã¯çŽ10ä¹è³90mgã®ãµãªã³ã
ãã¯ååç©ããã³çŽ100ä¹è³425mgã®ã¢ã»ãã¢ãã
ããšã³ãšããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽïŒä¹è³
100mgã®ãµãªã³ããã¯ååç©ããçŽ65ä¹è³450mgã®
ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã奜ãŸãã
æçšåäœã¯ãçŽ100ä¹è³425mgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«ããµãªã³ããã¯ååç©çŽ10ä¹è³90mgã§
ããã ååç© ïŒ£ äžèšã®æé ãçšããŠãïŒâïŒïŒâãããšããªã«
ã«ã«ããã«ïŒâããããªã³é žååç©ïŒä»¥åŸæã
ãããšã³ããŠãã³ååç©ããšãã¶ïŒã®é®çç¹æ§ã®
ã¢ã»ãã¢ããããšã³ã«ããçžä¹äœçšãäŸç€ºããã
ãšãã§ããããã®æ§è³ªã¯ããšã³ããŠãã³ïŒé žã®
圢ïŒãçšããããšã«ãã€ãŠäŸç€ºãããããããã
ãã«éå®ããããã®ã§ã¯ãªãããšã¯ç解ããã
ãã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第3aããã³ç¬¬3bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ããšã³ããŠãã³ããã³å¡©ãããããŠ15
ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸãã¯50
mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ããã³
ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£ã§äž
ããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯ŸããŠ20å¹
ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠãåæ§ã®æ°ã®
ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒKgïŒã
ãã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸãã¯ã¢ã»ãã¢ãã
ããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒ
KgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒïŒåæçšå
ãæçšããããããšã³ããŠãã³ã¯æ°Žæ§æžæ¿å€ãšã
ãŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§æžæ¿å€ãš
ããŠæäžããã ããšã³ããŠãã³ãæäžããŠ30ååŸïŒã¢ã»ãã¢ã
ãããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«
ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥
ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€
ã¯ã芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£
ãããã«é©çšããŠæ±ºå®ãããçµæã¯ç¬¬3aããã³
第3bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ïŒïŒ 劚害ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒççé£å¡©
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ãè¡šã
mlïŒKgïŒ
50
8ïŒ20 60(56)ïŒ 34.3(22.0â53.3)
25
11ïŒ20 45(39)ïŒ
15
13ïŒ20 35(28)ïŒ
10
15ïŒ20 25 (6)ïŒ
50
8ïŒ20 60(56)ïŒ 34.3(22.0â53.3)
25
11ïŒ20 45(39)ïŒ
15
13ïŒ20 35(28)ïŒ
10
15ïŒ20 25 (6)ïŒ
ãè¡šã
ïŒïŒ 劚害ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒççé£å¡©
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ2.2ä¹è³7.2mgïŒKgã®ããšã³
ããŠãã³ååç©ãçŽ1.9ä¹è³7.5mgïŒKgã®ã¢ã»ãã¢
ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜ãŸã
ãã¯ãçŽ2.5ä¹è³6.7mgã®ããšã³ããŠãã³ååç©ã
çŽ2.1ä¹è³7.1mgïŒKgã®ã¢ã»ãã¢ããããšã³ãšäžç·
ã«äœ¿çšãåŸãããšæ±ºå®ãããããããã®éã¯ãã
ãã«å¯ŸããŠå¥œé©ãªæçšéãšããŠè¡šãããšãçŽ129
ä¹è³430mgã®ããšã³ããŠãã³ååç©ããã³çŽ113ä¹
è³450mgã®ã¢ã»ãã¢ããããšã³ã奜ãŸããã¯çŽ150
ä¹è³400mgã®ããšã³ããŠãã³ååç©ããã³çŽ125ä¹
è³425mgã®ã¢ã»ãã¢ããããšã³ãšããç¯å²ã«ãªãã æçšåäœã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžžè¬ãå
è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéçããã³
ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®æçšå
äœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ129ä¹è³430mg
ã®ïŒâïŒïŒâãããšããªã«ã«ã«ããã«ïŒããããª
ã³é žååç©ããçŽ113ä¹è³450mgã®ã¢ã»ãã¢ããã
ãšã³ãšäžç·ã«å«æããã奜ãŸããæçšåäœã¯ãçŽ
125ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«ãïŒ
âïŒïŒâãããšããªã«ã«ã«ããã«ïŒããããªã³é ž
ååç©çŽ150ä¹è³400mgã§ããã ååç© ïŒ€ äžèšã®äœé ãçšããŠãïŒâã¡ããã·âαâã¡ã
ã«âïŒâããã¿ã¬ã³é ¢é žååç©ïŒä»¥åŸæã ããã
ããã»ã³ååç©ããšãã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢
ããããšã³ã«ããçžä¹äœçšãäŸç€ºããããšãã§ã
ãããã®æ§è³ªã¯ããããã»ã³ïŒé žã®åœ¢ïŒãçšãã
ããšã«ãã€ãŠäŸç€ºãããããããã ãã«éå®ãã
ããã®ã§ã¯ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第4aããã³ç¬¬4bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ããããã»ã³ããã³ççé£å¡©æ°Žããã
ããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸã
ã¯50mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ã
ãã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£
ã§äžããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯ŸããŠ
20å¹ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠãåæ§ã®
æ°ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒ
KgïŒããã³ççé£å¡©æ°ŽïŒ10mlïŒKgïŒãŸãã¯ã¢ã»ã
ã¢ããããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒ10
mlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒ10mlïŒKgïŒïŒåæ
çšåãæçšããããããããã»ã³ã¯æ°Žæ§æžæ¿å€ãš
ããŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§æžæ¿å€
ãšããŠæäžããã ããããã»ã³ãæäžããŠ30ååŸïŒã¢ã»ãã¢ãã
ããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«ã³
ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥ãã
è ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€ã¯ã
芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£ãã
ãã«é©çšããŠæ±ºå®ãããçµæã¯ç¬¬4aããã³ç¬¬4b
è¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ2.2ä¹è³7.2mgïŒKgã®ããšã³
ããŠãã³ååç©ãçŽ1.9ä¹è³7.5mgïŒKgã®ã¢ã»ãã¢
ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜ãŸã
ãã¯ãçŽ2.5ä¹è³6.7mgã®ããšã³ããŠãã³ååç©ã
çŽ2.1ä¹è³7.1mgïŒKgã®ã¢ã»ãã¢ããããšã³ãšäžç·
ã«äœ¿çšãåŸãããšæ±ºå®ãããããããã®éã¯ãã
ãã«å¯ŸããŠå¥œé©ãªæçšéãšããŠè¡šãããšãçŽ129
ä¹è³430mgã®ããšã³ããŠãã³ååç©ããã³çŽ113ä¹
è³450mgã®ã¢ã»ãã¢ããããšã³ã奜ãŸããã¯çŽ150
ä¹è³400mgã®ããšã³ããŠãã³ååç©ããã³çŽ125ä¹
è³425mgã®ã¢ã»ãã¢ããããšã³ãšããç¯å²ã«ãªãã æçšåäœã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžžè¬ãå
è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéçããã³
ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®æçšå
äœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ129ä¹è³430mg
ã®ïŒâïŒïŒâãããšããªã«ã«ã«ããã«ïŒããããª
ã³é žååç©ããçŽ113ä¹è³450mgã®ã¢ã»ãã¢ããã
ãšã³ãšäžç·ã«å«æããã奜ãŸããæçšåäœã¯ãçŽ
125ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«ãïŒ
âïŒïŒâãããšããªã«ã«ã«ããã«ïŒããããªã³é ž
ååç©çŽ150ä¹è³400mgã§ããã ååç© ïŒ€ äžèšã®äœé ãçšããŠãïŒâã¡ããã·âαâã¡ã
ã«âïŒâããã¿ã¬ã³é ¢é žååç©ïŒä»¥åŸæã ããã
ããã»ã³ååç©ããšãã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢
ããããšã³ã«ããçžä¹äœçšãäŸç€ºããããšãã§ã
ãããã®æ§è³ªã¯ããããã»ã³ïŒé žã®åœ¢ïŒãçšãã
ããšã«ãã€ãŠäŸç€ºãããããããã ãã«éå®ãã
ããã®ã§ã¯ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第4aããã³ç¬¬4bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ããããã»ã³ããã³ççé£å¡©æ°Žããã
ããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸã
ã¯50mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ã
ãã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£
ã§äžããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯ŸããŠ
20å¹ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠãåæ§ã®
æ°ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒ
KgïŒããã³ççé£å¡©æ°ŽïŒ10mlïŒKgïŒãŸãã¯ã¢ã»ã
ã¢ããããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒ10
mlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒ10mlïŒKgïŒïŒåæ
çšåãæçšããããããããã»ã³ã¯æ°Žæ§æžæ¿å€ãš
ããŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§æžæ¿å€
ãšããŠæäžããã ããããã»ã³ãæäžããŠ30ååŸïŒã¢ã»ãã¢ãã
ããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«ã³
ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥ãã
è ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€ã¯ã
芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£ãã
ãã«é©çšããŠæ±ºå®ãããçµæã¯ç¬¬4aããã³ç¬¬4b
è¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ïŒïŒ 劚害ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒççé£å¡©
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ãè¡šã
ïŒïŒ ã¢ã»ãã¢ããããšã³ïŒççé£å¡©æ°Žã®åå¿
ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ1.4ä¹è³2.1mgïŒKgã®ããã
ãã»ã³ååç©ãçŽ2.8ä¹è³7.5mgïŒKgã®ã¢ã»ãã¢ã
ãããšã³ãšäžç·ã«äœ¿çšããããšãã§ããããšæ±ºå®
ãããããããã®éã¯ãããã«é©ããæçšéãšã
ãŠè¡šãããšãçŽ85ä¹è³125mgã®ããããã»ã³åå
ç©ããã³çŽ170ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ãš
ããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ85ä¹è³
125mgã®ïŒâã¡ããã·âαâïŒâããã¿ã¬ã³é ¢é ž
ååç©ããçŽ170ä¹è³450mgã®ã¢ã»ãã¢ããããšã³
ãšäžç·ã«å«æããã ååç© ïŒ¥ äžèšã®æé ãçšããŠãïœâãã³ãŸã€ã«ãããã¢
ãããé žååç©ïŒä»¥åŸæã ãã±ãããããšã³åå
ç©ããšãã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«
ããçžä¹äœçšãäŸç€ºããããšãã§ããããã®æ§è³ª
ã¯ã±ãããããšã³ïŒé žã®åœ¢ïŒãçšããããšã«ãã€
ãŠäŸç€ºãããããããã ãã«éå®ããããã®ã§ã¯
ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第5aããã³ç¬¬5bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ã±ãããããšã³ããã³å¡©ãããããŠ15
ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸãã¯50
mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ããã³
ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£ã§äž
ããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯ŸããŠ20å¹
ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠãåæ§ã®æ°ã®
ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒKgïŒã
ãã³ççé£å¡©æ°ŽïŒ10mlïŒKgïŒãŸãã¯ã¢ã»ãã¢ãã
ããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒ10mlïŒ
KgïŒããã³(b)ççé£å¡©æ°ŽïŒ10mlïŒKgïŒïŒåæçšå
ãæçšããããã±ãããããšã³ã¯æ°Žé žåãããªãŠ
ã 氎溶液äžã®æº¶æ¶²ãšããŠæäžãããã¢ã»ãã¢ãã
ããšã³ã¯æ°Žæ§æžæ¿å€ãšããŠæäžãããïŒãmgïŒKgã
ãŸãã¯ãmlïŒKgããçšããããŠããå Žåã¯ããKgã
ã¯äœéã«ããããã®ã§ãããïŒ ã±ãããããšã³ãæäžããŠ20ååŸïŒã¢ã»ãã¢ã
ãããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«
ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥
ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€
ã¯ã芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£
ãããã«é©çšããŠæ±ºå®ãããçµæã第5aããã³
第5bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ1.4ä¹è³2.1mgïŒKgã®ããã
ãã»ã³ååç©ãçŽ2.8ä¹è³7.5mgïŒKgã®ã¢ã»ãã¢ã
ãããšã³ãšäžç·ã«äœ¿çšããããšãã§ããããšæ±ºå®
ãããããããã®éã¯ãããã«é©ããæçšéãšã
ãŠè¡šãããšãçŽ85ä¹è³125mgã®ããããã»ã³åå
ç©ããã³çŽ170ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ãš
ããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ85ä¹è³
125mgã®ïŒâã¡ããã·âαâïŒâããã¿ã¬ã³é ¢é ž
ååç©ããçŽ170ä¹è³450mgã®ã¢ã»ãã¢ããããšã³
ãšäžç·ã«å«æããã ååç© ïŒ¥ äžèšã®æé ãçšããŠãïœâãã³ãŸã€ã«ãããã¢
ãããé žååç©ïŒä»¥åŸæã ãã±ãããããšã³åå
ç©ããšãã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢ããããšã³ã«
ããçžä¹äœçšãäŸç€ºããããšãã§ããããã®æ§è³ª
ã¯ã±ãããããšã³ïŒé žã®åœ¢ïŒãçšããããšã«ãã€
ãŠäŸç€ºãããããããã ãã«éå®ããããã®ã§ã¯
ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第5aããã³ç¬¬5bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ã±ãããããšã³ããã³å¡©ãããããŠ15
ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸãã¯50
mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ããã³
ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£ã§äž
ããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯ŸããŠ20å¹
ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠãåæ§ã®æ°ã®
ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒKgïŒã
ãã³ççé£å¡©æ°ŽïŒ10mlïŒKgïŒãŸãã¯ã¢ã»ãã¢ãã
ããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒ10mlïŒ
KgïŒããã³(b)ççé£å¡©æ°ŽïŒ10mlïŒKgïŒïŒåæçšå
ãæçšããããã±ãããããšã³ã¯æ°Žé žåãããªãŠ
ã 氎溶液äžã®æº¶æ¶²ãšããŠæäžãããã¢ã»ãã¢ãã
ããšã³ã¯æ°Žæ§æžæ¿å€ãšããŠæäžãããïŒãmgïŒKgã
ãŸãã¯ãmlïŒKgããçšããããŠããå Žåã¯ããKgã
ã¯äœéã«ããããã®ã§ãããïŒ ã±ãããããšã³ãæäžããŠ20ååŸïŒã¢ã»ãã¢ã
ãããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ãã«
ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³šå ¥
ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®å€
ã¯ã芳枬ãããå€ãããåã«è°è«ããé©åãªè£æ£
ãããã«é©çšããŠæ±ºå®ãããçµæã第5aããã³
第5bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ïŒïŒ 劚害ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒççé£å¡©
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ãè¡šã
ïŒïŒ 劚害ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒççé£å¡©
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ0.2ä¹è³0.83mgïŒKgã®ã±ã
ããããšã³ååç©ãçŽ2.8ä¹è³7.5mgïŒKgã®ã¢ã»ã
ã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜ãŸ
ããã¯çŽ0.33ä¹è³0.67mgïŒKgã®ã±ãããããšã³å
åç©ãçŽ3.3ä¹è³7.1mgïŒKgã®ã¢ã»ãã¢ããããšã³
ãšäžç·ã«äœ¿çšãåŸãããšæ±ºå®ãããããããã®é
ã¯ãããã«é©ããæçšéãšããŠè¡šãããšãçŽ12ä¹
è³50mgã®ã±ãããããšã³ååç©ããã³çŽ170ä¹è³
450mgã®ã¢ã»ãã¢ããããšã³ã奜ãŸããã¯çŽ20ä¹
è³40mgã®ã±ãããããšã³ååç©ããã³çŽ200ä¹è³
245mgã®ã¢ã»ãã¢ããããšã³ãšããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ12ä¹è³
50mgã®ïœâãã³ãŸã€ã«ãããã¢ãããé žååç©
ïŒã±ãããããšã³ååç©ïŒããçŽ170ä¹è³450mgã®
ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã奜ãŸãã
æçšåäœã¯ãçŽ200ä¹è³425mgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«ãïœâãã³ãŸã€ã«ãããã¢ãããé žå
åç©çŽ20ä¹è³40mgã§ããã ååç© ïŒŠ äžèšã®æé ãçšããŠãïŒâïŒïŒïŒïŒâãžããã
âïŒâãªããœâ2Hâã€ãœã€ã³ããŒã«âïŒâã€ã«ïŒ
âαâã¡ãã«ãã³ãŒã³é ¢é žååç©ïŒä»¥åŸã¯æã
ãã€ã³ãããããšã³ååç©ããšãã¶ïŒã®é®çç¹æ§
ã®ã¢ã»ãã¢ããããšã³ã«ããçžä¹äœçšãäŸç€ºãã
ããšãã§ããããã®æ§è³ªã¯ã€ã³ãããããšã³ïŒé ž
ã®åœ¢ïŒãçšããããšã«ãã€ãŠäŸç€ºããããããã
ã ãã«éå®ããããã®ã§ã¯ãªãããšã¯ç解ããã
ãã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第6aããã³ç¬¬6bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ã€ã³ãããããšã³ããã³ççé£å¡©æ°Ž
ãããããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒ
KgãŸãã¯50mgïŒKgããçµå£çã«æçšããããè©Šéš
è¬å€ããã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæº
ã¯ãçµå£ã§äžããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæº
ã«å¯ŸããŠ20å¹ã®ããŠã¹ãçšãããç §æ»æšæºãšã
ãŠãåæ°ã®æ°ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³
ïŒ25mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸã
ã¯ã¢ã»ãã¢ããããšã³ïŒ50mgïŒKgïŒããã³ççé£
å¡©æ°ŽïŒïŒmlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒ
KgïŒïŒåæçšåãæçšããããã€ã³ãããããšã³
ã¯æ°Žæ§æžæ¿å€ãšããŠæäžãããã¢ã»ãã¢ããããš
ã³ã¯æ°Žæ§æžæ¿å€ãšããŠæäžããã ã€ã³ãããããšã³ãæäžããŠ30ååŸïŒã¢ã»ãã¢
ããããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ã
ã«ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³š
å ¥ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®
å€ã¯ã芳枬ãããå€ãããé©åœãªãšããã§åã«è°
è«ããè£æ£ãé©çšããŠã決å®ãããçµæã¯ç¬¬6a
ããã³ç¬¬6bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ0.2ä¹è³0.83mgïŒKgã®ã±ã
ããããšã³ååç©ãçŽ2.8ä¹è³7.5mgïŒKgã®ã¢ã»ã
ã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜ãŸ
ããã¯çŽ0.33ä¹è³0.67mgïŒKgã®ã±ãããããšã³å
åç©ãçŽ3.3ä¹è³7.1mgïŒKgã®ã¢ã»ãã¢ããããšã³
ãšäžç·ã«äœ¿çšãåŸãããšæ±ºå®ãããããããã®é
ã¯ãããã«é©ããæçšéãšããŠè¡šãããšãçŽ12ä¹
è³50mgã®ã±ãããããšã³ååç©ããã³çŽ170ä¹è³
450mgã®ã¢ã»ãã¢ããããšã³ã奜ãŸããã¯çŽ20ä¹
è³40mgã®ã±ãããããšã³ååç©ããã³çŽ200ä¹è³
245mgã®ã¢ã»ãã¢ããããšã³ãšããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ12ä¹è³
50mgã®ïœâãã³ãŸã€ã«ãããã¢ãããé žååç©
ïŒã±ãããããšã³ååç©ïŒããçŽ170ä¹è³450mgã®
ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã奜ãŸãã
æçšåäœã¯ãçŽ200ä¹è³425mgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«ãïœâãã³ãŸã€ã«ãããã¢ãããé žå
åç©çŽ20ä¹è³40mgã§ããã ååç© ïŒŠ äžèšã®æé ãçšããŠãïŒâïŒïŒïŒïŒâãžããã
âïŒâãªããœâ2Hâã€ãœã€ã³ããŒã«âïŒâã€ã«ïŒ
âαâã¡ãã«ãã³ãŒã³é ¢é žååç©ïŒä»¥åŸã¯æã
ãã€ã³ãããããšã³ååç©ããšãã¶ïŒã®é®çç¹æ§
ã®ã¢ã»ãã¢ããããšã³ã«ããçžä¹äœçšãäŸç€ºãã
ããšãã§ããããã®æ§è³ªã¯ã€ã³ãããããšã³ïŒé ž
ã®åœ¢ïŒãçšããããšã«ãã€ãŠäŸç€ºããããããã
ã ãã«éå®ããããã®ã§ã¯ãªãããšã¯ç解ããã
ãã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第6aããã³ç¬¬6bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ã€ã³ãããããšã³ããã³ççé£å¡©æ°Ž
ãããããŠ15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒ
KgãŸãã¯50mgïŒKgããçµå£çã«æçšããããè©Šéš
è¬å€ããã³ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæº
ã¯ãçµå£ã§äžããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæº
ã«å¯ŸããŠ20å¹ã®ããŠã¹ãçšãããç §æ»æšæºãšã
ãŠãåæ°ã®æ°ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³
ïŒ25mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒïŒmlïŒKgïŒãŸã
ã¯ã¢ã»ãã¢ããããšã³ïŒ50mgïŒKgïŒããã³ççé£
å¡©æ°ŽïŒïŒmlïŒKgïŒããã³(b)ççé£å¡©æ°ŽïŒïŒmlïŒ
KgïŒïŒåæçšåãæçšããããã€ã³ãããããšã³
ã¯æ°Žæ§æžæ¿å€ãšããŠæäžãããã¢ã»ãã¢ããããš
ã³ã¯æ°Žæ§æžæ¿å€ãšããŠæäžããã ã€ã³ãããããšã³ãæäžããŠ30ååŸïŒã¢ã»ãã¢
ããããšã³ãæäžããŠ15ååŸïŒãããŠã¹ã«ã¢ã»ã
ã«ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èãéããŠæ³š
å ¥ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ãããED50ã®
å€ã¯ã芳枬ãããå€ãããé©åœãªãšããã§åã«è°
è«ããè£æ£ãé©çšããŠã決å®ãããçµæã¯ç¬¬6a
ããã³ç¬¬6bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ïŒïŒ ãã®åã®åŠšå®³ïŒ
ã¯ã¢ã»ãã¢ããããšã³ïŒ
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ãè¡šã
ãè¡šã
ïŒ åŠšå®³ïŒ
ã¯ççé£å¡©æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒ åŠšå®³ïŒ ã¯ã¢ã»ãã¢ããããšã³ïŒççé£å¡©
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ0.17ä¹è³2.5mgïŒKgã®ã€ã³
ãããããšã³ååç©ãçŽ2.2ä¹è³7.5mgïŒKgã®ã¢ã»
ãã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜
ãŸããã¯çŽ0.58ä¹è³2.2mgïŒKgã®ã€ã³ãããããš
ã³ååç©ãçŽ2.5ä¹è³7.1mgïŒKgã®ã¢ã»ãã¢ããã
ãšã³ãšäžç·ã«äœ¿çšãåŸãããšæ±ºå®ããããããã
ã®éã¯ãããã«é©ããæçšéãšããŠè¡šãããšãçŽ
25ä¹è³150mgã®ã€ã³ãããããšã³ååç©ããã³çŽ
135ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ã奜ãŸããã¯
çŽ35ä¹è³130mgã®ã€ã³ãããããšã³ååç©ããã³
çŽ150ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšããç¯å²
ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ25ä¹è³
150mgã®ã€ã³ãããããšã³ååç©ããçŽ150ä¹è³
450mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã
奜ãŸããæçšåäœã¯ãçŽ150ä¹è³425mgã®ã¢ã»ãã¢
ããããšã³ãšäžç·ã«ãã€ã³ãããããšã³ååç©çŽ
35ä¹è³130mgã§ããã ååç© ïŒ§ äžèšã®æé ãçšããŠãαâã¡ãã«âïŒâããšã
ãã·ãã³ãŒã³é ¢é žååç©ïŒä»¥åŸã¯æã ãããšãã
ãããšã³ååç©ããšãã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢
ããããšã³ã«ããçžä¹äœçšãäŸç€ºããããšãã§ã
ãããã®æ§è³ªã¯ããšãããããšã³ã®ãããªãŠã å¡©
ãçšããããšã«ãã€ãŠäŸç€ºãããããããã ãã«
éå®ããããã®ã§ã¯ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第7aããã³ç¬¬7bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ããšãããããšã³ããã³å¡©ãããããŠ
15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸãã¯50
mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ããã³
ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£ã§äž
ããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯Ÿãã20å¹
ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠã¯ãåæ§ã®æ°
ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒKgïŒ
ããã³ççé£å¡©æ°ŽïŒ10mlïŒKgïŒãŸãã¯ã¢ã»ãã¢ã
ãããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒ10mlïŒ
KgïŒããã³(b)ççé£å¡©æ°ŽïŒ10mlïŒKgïŒïŒåæçšå
ãæçšããããããšãããããšã³ãããªãŠã ã¯æ°Ž
溶液ãšããŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§
æžæ¿å€ãšããŠæäžããã ããšãããããšã³ãããªãŠã ãæäžããŠ30ååŸ
ïŒã¢ã»ãã¢ããããšã³ãæäžããŠ15ååŸïŒãããŠã¹
ã«ã¢ã»ãã«ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èã
éããŠæ³šå ¥ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ããã
ED50ã®å€ã¯ã芳枬ãããå€ãããé©åãªæã§å
ã«è°è«ããè£æ£ãé©çšããŠã決å®ãããçµæã第
7aããã³ç¬¬7bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ïŒïŒ åŠšå®³ïŒ ã¯ã¢ã»ãã¢ããããšã³ïŒççé£å¡©
æ°Žã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ0.17ä¹è³2.5mgïŒKgã®ã€ã³
ãããããšã³ååç©ãçŽ2.2ä¹è³7.5mgïŒKgã®ã¢ã»
ãã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§ãã奜
ãŸããã¯çŽ0.58ä¹è³2.2mgïŒKgã®ã€ã³ãããããš
ã³ååç©ãçŽ2.5ä¹è³7.1mgïŒKgã®ã¢ã»ãã¢ããã
ãšã³ãšäžç·ã«äœ¿çšãåŸãããšæ±ºå®ããããããã
ã®éã¯ãããã«é©ããæçšéãšããŠè¡šãããšãçŽ
25ä¹è³150mgã®ã€ã³ãããããšã³ååç©ããã³çŽ
135ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ã奜ãŸããã¯
çŽ35ä¹è³130mgã®ã€ã³ãããããšã³ååç©ããã³
çŽ150ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšããç¯å²
ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ25ä¹è³
150mgã®ã€ã³ãããããšã³ååç©ããçŽ150ä¹è³
450mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«å«æããã
奜ãŸããæçšåäœã¯ãçŽ150ä¹è³425mgã®ã¢ã»ãã¢
ããããšã³ãšäžç·ã«ãã€ã³ãããããšã³ååç©çŽ
35ä¹è³130mgã§ããã ååç© ïŒ§ äžèšã®æé ãçšããŠãαâã¡ãã«âïŒâããšã
ãã·ãã³ãŒã³é ¢é žååç©ïŒä»¥åŸã¯æã ãããšãã
ãããšã³ååç©ããšãã¶ïŒã®é®çç¹æ§ã®ã¢ã»ãã¢
ããããšã³ã«ããçžä¹äœçšãäŸç€ºããããšãã§ã
ãããã®æ§è³ªã¯ããšãããããšã³ã®ãããªãŠã å¡©
ãçšããããšã«ãã€ãŠäŸç€ºãããããããã ãã«
éå®ããããã®ã§ã¯ãªãããšã¯ç解ããããã 18â24ïœã®æé£ãããŠããªããªã¹ã®çœããã¿
ã«ãæåã第7aããã³ç¬¬7bè¡šã«ç€ºãåŠããçš®ã
ã®æçšéã®ããšãããããšã³ããã³å¡©ãããããŠ
15ååŸã«ã¯ã¢ã»ãã¢ããããšã³25mgïŒKgãŸãã¯50
mgïŒKgããçµå£çã«æçšããããè©Šéšè¬å€ããã³
ççé£å¡©æ°Žã®ç §æ»æšæºã®å šæçšæ°Žæºã¯ãçµå£ã§äž
ããŸãçµå£ã§è¡šç€ºãããåæçšæ°Žæºã«å¯Ÿãã20å¹
ã®ããŠã¹ãçšãããç §æ»æšæºãšããŠã¯ãåæ§ã®æ°
ã®ããŠã¹ã«ã(a)ã¢ã»ãã¢ããããšã³ïŒ25mgïŒKgïŒ
ããã³ççé£å¡©æ°ŽïŒ10mlïŒKgïŒãŸãã¯ã¢ã»ãã¢ã
ãããšã³ïŒ50mgïŒKgïŒããã³ççé£å¡©æ°ŽïŒ10mlïŒ
KgïŒããã³(b)ççé£å¡©æ°ŽïŒ10mlïŒKgïŒïŒåæçšå
ãæçšããããããšãããããšã³ãããªãŠã ã¯æ°Ž
溶液ãšããŠæäžãããã¢ã»ãã¢ããããšã³ã¯æ°Žæ§
æžæ¿å€ãšããŠæäžããã ããšãããããšã³ãããªãŠã ãæäžããŠ30ååŸ
ïŒã¢ã»ãã¢ããããšã³ãæäžããŠ15ååŸïŒãããŠã¹
ã«ã¢ã»ãã«ã³ãªã³ãããã€ã5.5mgïŒKgãè ¹èã
éããŠæ³šå ¥ããè ¹éšåçž®åå¿ã®ååŠã芳å¯ããã
ED50ã®å€ã¯ã芳枬ãããå€ãããé©åãªæã§å
ã«è°è«ããè£æ£ãé©çšããŠã決å®ãããçµæã第
7aããã³ç¬¬7bè¡šã«ç€ºãã ïŒãmgïŒKgããŸãã¯ãmlïŒKgããçšããããŠã
ãå Žåã¯ããKgãã¯äœéã«ããããã®ã§ãããïŒ
ãè¡šã
ïŒïŒ 劚害ïŒ
ã¯ããšãããããšã³ïŒççé£å¡©æ°Ž
ã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ãè¡šã
ïŒïŒ 劚害ïŒ
ã¯ããšãããããšã³ïŒççé£å¡©æ°Ž
ã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ1.4ä¹è³2.8mgïŒKgäœéã®ã
ãšãããããšã³ååç©ãçŽ3.8ä¹è³7.5mgïŒKgäœé
ã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§
ãã奜ãŸããã¯çŽ1.5ä¹è³2.5mgïŒKgäœéã®ããšã
ããããšã³ååç©ãçŽ4.2ä¹è³7.1mgïŒKgäœéã®ã¢
ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšãåŸãããšæ±ºå®ã
ããããããã®éã¯ãããã«é©ããæçšéãšããŠ
è¡šãããšãçŽ84ä¹è³168mgã®ããšãããããšã³å
åç©ããã³çŽ225ä¹è³450mgã®ã¢ã»ãã¢ããããš
ã³ã奜ãŸããã¯çŽ90ä¹è³150mgã®ããšãããããš
ã³ååç©ããã³çŽ250ä¹è³425mgã®ã¢ã»ãã¢ããã
ãšã³ãšããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ85ä¹è³
168mgã®Î±âã¡ãã«âïŒâããšããã·ãã³ãŒã³é ¢
é žååç©ããçŽ225ä¹è³450mgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«å«æããã奜ãŸããæçšåäœã¯ãçŽ
250ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«ãα
âã¡ãã«âïŒâããšããã·ãã³ãŒã³é ¢é žååç©çŽ
90ä¹è³150mgã§ããã 次ã®å®æœäŸã¯æ°èŠãªçµæç©ãäŸç€ºããããã«ç€º
ãããã®ã§ããã粟ç¥ãŸãã¯ç¯å²ã«æŒããŠæ¬çºæ
ãéå®ããæå³ã§ã¯ãªãã ååç© ïŒ¡ å®æœäŸ ïŒ åã 15mgã®ïŒâãïŒïŒïŒïŒâãžã¯ããããšãã«ïŒ
ã¢ããããã³ãŒã³é ¢é žïŒãžã¯ãããšããã¯ïŒãäž»
掻æ§æåãšããŠå«æã280mgã®ã¢ã»ãã¢ããããš
ã³ãçžä¹äœçšå€ãšããŠå«æããã1000åã®ç¡¬ãŒã©
ãã³ã«ãã»ã«å€ãã次ã®çµæãã補é ããïŒ ïœ ãžã¯ãããšãã㯠15 ã¢ã»ãã¢ããããšã³ 280 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå å¡«ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããããšã«ãã€ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«
䜿çšããã®ã奜é©ã§ããã å®æœäŸ ïŒ çµæäžã15ïœã®ãããªãŠã ïŒâãïŒïŒïŒâãžã¯
ããããšãã«ïŒã¢ããããã³ãŒã³é ¢é žïŒãžã¯ãã
ãšããã¯ãããªãŠã ïŒã䞻掻æ§æåãçšããç¹ã
é€ãã°å®æœäŸïŒèšèŒã®åŠãã«ãŒã©ãã³ã«ãã»ã«å€
ã補é ãã280ïœã®ã¢ã»ãã¢ããããšã³ãçžä¹äœ
çšå€ãšããŠäœ¿çšããããããŠåã 15mgã®ãžã¯ãã
ãšããã¯ãããªãŠã ããã³280mgã®ã¢ã»ãã¢ãã
ããšã³ãå«æããã«ãã»ã«å€ãæäŸããã å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠïŒmgã®ãžã¯ãããšããã¯ãã
ã³çžä¹äœçšå€ãšããŠ450mgã®ã¢ã»ãã¢ããããšã³
ãåã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã
補é ããïŒ ïœ ãžã¯ãããšããã¯ ïŒ ã¢ã»ãã¢ããããšã³ 450 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 现ããç²æ«åããæåãããæ··åãã10ïŒ ã®ã
ã³ãã³ããŒã¹ããçšããŠç²å€åãããç²å€ã也ç¥
ããå§çž®ããŠé å€ãšããã ååç© ïŒ¢ å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ10mgã®ãµãªã³ããã¯ããã³çž
ä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«ãã»ã«å€ã次
ã®çµæãã補é ããïŒ ïœ ãµãªã³ãã㯠10 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå å¡«ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããããšã«ãã€ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«
䜿çšããã®ã奜é©ã§ããã å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ10mgã®ãµãªã³ããã¯ããã³çž
ä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ãµãªã³ãã㯠10 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ããçšããŠç²å€åãããç²å€ã也ç¥ãã
å§çž®ããŠé å€ãšããã ååç© ïŒ£ å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ275mgã®ïŒâïŒïŒâãããšã
ãªã«ã«ã«ããã«ïŒããããªã³é žïŒããšã³ããŠã
ã³ïŒããã³çžä¹äœçšå€ãšããŠ275mgã®ã¢ã»ãã¢ã
ãããšã³ãåã å«æãã1000åã®ã®ç¡¬ãŒã©ãã³ã«
ãã»ã«å€ã次ã®çµæãã補é ããïŒ ïœ ããšã³ããŠãã³ 275 ã¢ã»ãã¢ããããšã³ 275 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã
奜é©ã§ããã å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ275mgã®ããšã³ããŠãã³ãã
ã³çžä¹äœçšå€ãšããŠ275mgã®ã¢ã»ãã¢ããããšã³
ãåã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã
補é ããïŒ ïœ ããšã³ããŠãã³ 275 ã¢ã»ãã¢ããããšã³ 275 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ãã§ç²å€åãããç²å€ã也ç¥ãããŠå§çž®
ããŠé å€ãšããã ååç© ïŒ€ å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ105mgã®ïŒïŒïŒâïŒâã¡ãã
ã·âαâã¡ãã«âïŒâããã¿ã¬ã³é ¢é žïŒïŒããã
ã»ã³ïŒããã³çžä¹äœçšå€ãšããŠ310mgã®ã¢ã»ãã¢
ããããšã³ãåã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«
ãã»ã«å€ã次ã®çµæãã補é ããïŒ ïœ ããããã»ã³ 105 ã¢ã»ãã¢ããããšã³ 310 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãæºããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯çã¿ã«èŠãã被æ€äœã«æäžã
ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã奜
é©ã§ããã å®æœäŸ ïŒ çµæäžã115ïœã®ãããªãŠã âïŒâã¡ããã·â
αâã¡ãã«âïŒâããã¿ã¬ã³ã¢ã»ããŒãïŒããã
ãã»ã³ãããªãŠã ïŒã䞻掻æ§æåãšããŠäœ¿çšã
350ïœã®ã¢ã»ãã¢ããããšã³ãçžä¹äœçšå€ãšããŠ
䜿çšããç¹ä»¥å€ã¯å®æœäŸïŒèšèŒã®åŠãã«ããŠããŒ
ã©ãã³ã«ãã»ã«ã補é ãããšãããããŠåã 115
mgã®ããããã»ã³ãããªãŠã ããã³350mgã®ã¢ã»
ãã¢ããããšã³ãå«æããã«ãã»ã«å€ãæäŸãã
ãã å®æœäŸ 10 䞻掻æ§æåãšããŠ115mgã®ããããã»ã³ããã³
çžä¹äœçšå€ãšããŠ350mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ããããã»ã³ 90 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ããçšããŠç²å€ãšãããç²å€ã也ç¥ãã
ãŠå§çž®ãé å€ãšããã ååç© ïŒ¥ å®æœäŸ 11 䞻掻æ§æåãšããŠ30mgã®ïœâãã³ãŸã€ã«ããã
ã¢ãããé žïŒã±ãããããšã³ïŒããã³çžä¹äœçšå€
ãšããŠ350mgã®ã¢ã»ãã¢ããããšã³ãåã å«æã
ã1000åã®ç¡¬ãŒã©ãã³ã«ãã»ã«å€ã次ã®çµæãã
補é ããïŒ ïœ ã±ãããããšã³ 30 ã¢ã»ãã¢ããããšã³ 350 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 æåã®åäžãªæ··åç©ã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããŠãæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®
ã奜é©ã§ããã å®æœäŸ 12 䞻掻æ§æåãšããŠ20mgã®ã±ãããããšã³ããã³
çžä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ã±ãããããšã³ 20 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ããçšããŠç²å€ãšãããç²å€ã也ç¥ãã
å§çž®ããŠé å€ãšããã ååç© ïŒŠ å®æœäŸ 13 䞻掻æ§æåãšããŠ85mgã®ïŒâïŒïŒïŒïŒâãžãã
ãâïŒâãªããœâ2Hâã€ãœã€ã³ããŒã«âïŒâã€
ã«ïŒâαâã¡ãã«ãã³ãŒã³é ¢é žïŒã€ã³ãããããš
ã³ïŒããã³çžä¹äœçšå€ãšããŠ280mgã®ã¢ã»ãã¢ã
ãããšã³ãåã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«ã
ã»ã«å€ã次ã®çµæãã補é ããïŒ ïœ ã€ã³ãããããšã³ 85 ã¢ã»ãã¢ããããšã³ 280 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åç©ãé åã«ãã€ãŠè£œé ãã
ïŒçåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯çã¿ã«èŠãã被æ€äœã«æäžã
ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã奜
é©ã§ããã å®æœäŸ 14 䞻掻æ§å€ãšããŠ35mgã®ã€ã³ãããããšã³ããã³
çžä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ã€ã³ãããããšã³ 35 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ãã§ç²å€ãšãããç²å€ã也ç¥ããå§çž®ã
ãŠé å€ãšããã ååç© ïŒ§ å®æœäŸ 15 䞻掻æ§æåãšããŠ120mgã®Î±âã¡ãã«âïŒâã
ãšããã·ãã³ãŒã³é ¢é žïŒããšãããããšã³ïŒãã
ã³çžä¹äœçšå€ãšããŠ340mgã®ã¢ã»ãã¢ããããšã³
ãåã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«ãã»ã«å€ã
次ã®çµæãã補é ããïŒ ïœ ããšãããããšã³ 120 ã¢ã»ãã¢ããããšã³ 340 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åç©ãé åã«ãã€ãŠè£œé ãã
ïŒçåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯çã¿ã«èŠãã被æ€äœã«æäžã
ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã奜
é©ã§ããã å®æœäŸ 16 䞻掻æ§æåãšããŠ100mgã®ããšãããããšã³ã
ãã³çžä¹äœçšå€ãšããŠ400mgã®ã¢ã»ãã¢ããããš
ã³ãåã å«æãã1000åã®å§æœ°é å€ã次ã®çµæã
ã補é ããïŒ ïœ ããšãããããšã³ 100 ã¢ã»ãã¢ããããšã³ 400 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ãã§ç²å€ãšãããç²å€ã也ç¥ããå§çž®ã
ãŠé å€ãšããã
ã®åå¿ã«å¯ŸããŠè£æ£
ïŒïŒïŒ ä¿¡é Œéç
ããŠã¹ã«ä¿ãäžèšã®è©Šéšçµæããã³åç¬ã«äœ¿çš
ããæã®ããã«å¯ŸããŠäœ¿çšããæåã®å ¬ç¥ã®æçš
ç¯å²ãããäžè¬ã«ãçŽ1.4ä¹è³2.8mgïŒKgäœéã®ã
ãšãããããšã³ååç©ãçŽ3.8ä¹è³7.5mgïŒKgäœé
ã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšããããšãã§
ãã奜ãŸããã¯çŽ1.5ä¹è³2.5mgïŒKgäœéã®ããšã
ããããšã³ååç©ãçŽ4.2ä¹è³7.1mgïŒKgäœéã®ã¢
ã»ãã¢ããããšã³ãšäžç·ã«äœ¿çšãåŸãããšæ±ºå®ã
ããããããã®éã¯ãããã«é©ããæçšéãšããŠ
è¡šãããšãçŽ84ä¹è³168mgã®ããšãããããšã³å
åç©ããã³çŽ225ä¹è³450mgã®ã¢ã»ãã¢ããããš
ã³ã奜ãŸããã¯çŽ90ä¹è³150mgã®ããšãããããš
ã³ååç©ããã³çŽ250ä¹è³425mgã®ã¢ã»ãã¢ããã
ãšã³ãšããç¯å²ã«ãªãã æçšåäœã®åœ¢ã®äŸã¯ãé å€ãã«ãã»ã«å€ãäžž
è¬ãå è£ æ£å€ããŠãšãŒããŒå€ãè¶åéã倧åéç
ããã³ãããã®ãã®ã®åé¢å€æ§åœ¢ã§ãããäžã€ã®
æçšåäœã¯ãäžè¬ã«ã䞻掻æ§æåãšããŠçŽ85ä¹è³
168mgã®Î±âã¡ãã«âïŒâããšããã·ãã³ãŒã³é ¢
é žååç©ããçŽ225ä¹è³450mgã®ã¢ã»ãã¢ããããš
ã³ãšäžç·ã«å«æããã奜ãŸããæçšåäœã¯ãçŽ
250ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãšäžç·ã«ãα
âã¡ãã«âïŒâããšããã·ãã³ãŒã³é ¢é žååç©çŽ
90ä¹è³150mgã§ããã 次ã®å®æœäŸã¯æ°èŠãªçµæç©ãäŸç€ºããããã«ç€º
ãããã®ã§ããã粟ç¥ãŸãã¯ç¯å²ã«æŒããŠæ¬çºæ
ãéå®ããæå³ã§ã¯ãªãã ååç© ïŒ¡ å®æœäŸ ïŒ åã 15mgã®ïŒâãïŒïŒïŒïŒâãžã¯ããããšãã«ïŒ
ã¢ããããã³ãŒã³é ¢é žïŒãžã¯ãããšããã¯ïŒãäž»
掻æ§æåãšããŠå«æã280mgã®ã¢ã»ãã¢ããããš
ã³ãçžä¹äœçšå€ãšããŠå«æããã1000åã®ç¡¬ãŒã©
ãã³ã«ãã»ã«å€ãã次ã®çµæãã補é ããïŒ ïœ ãžã¯ãããšãã㯠15 ã¢ã»ãã¢ããããšã³ 280 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå å¡«ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããããšã«ãã€ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«
䜿çšããã®ã奜é©ã§ããã å®æœäŸ ïŒ çµæäžã15ïœã®ãããªãŠã ïŒâãïŒïŒïŒâãžã¯
ããããšãã«ïŒã¢ããããã³ãŒã³é ¢é žïŒãžã¯ãã
ãšããã¯ãããªãŠã ïŒã䞻掻æ§æåãçšããç¹ã
é€ãã°å®æœäŸïŒèšèŒã®åŠãã«ãŒã©ãã³ã«ãã»ã«å€
ã補é ãã280ïœã®ã¢ã»ãã¢ããããšã³ãçžä¹äœ
çšå€ãšããŠäœ¿çšããããããŠåã 15mgã®ãžã¯ãã
ãšããã¯ãããªãŠã ããã³280mgã®ã¢ã»ãã¢ãã
ããšã³ãå«æããã«ãã»ã«å€ãæäŸããã å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠïŒmgã®ãžã¯ãããšããã¯ãã
ã³çžä¹äœçšå€ãšããŠ450mgã®ã¢ã»ãã¢ããããšã³
ãåã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã
補é ããïŒ ïœ ãžã¯ãããšããã¯ ïŒ ã¢ã»ãã¢ããããšã³ 450 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 现ããç²æ«åããæåãããæ··åãã10ïŒ ã®ã
ã³ãã³ããŒã¹ããçšããŠç²å€åãããç²å€ã也ç¥
ããå§çž®ããŠé å€ãšããã ååç© ïŒ¢ å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ10mgã®ãµãªã³ããã¯ããã³çž
ä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«ãã»ã«å€ã次
ã®çµæãã補é ããïŒ ïœ ãµãªã³ãã㯠10 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå å¡«ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããããšã«ãã€ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«
䜿çšããã®ã奜é©ã§ããã å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ10mgã®ãµãªã³ããã¯ããã³çž
ä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ãµãªã³ãã㯠10 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ããçšããŠç²å€åãããç²å€ã也ç¥ãã
å§çž®ããŠé å€ãšããã ååç© ïŒ£ å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ275mgã®ïŒâïŒïŒâãããšã
ãªã«ã«ã«ããã«ïŒããããªã³é žïŒããšã³ããŠã
ã³ïŒããã³çžä¹äœçšå€ãšããŠ275mgã®ã¢ã»ãã¢ã
ãããšã³ãåã å«æãã1000åã®ã®ç¡¬ãŒã©ãã³ã«
ãã»ã«å€ã次ã®çµæãã補é ããïŒ ïœ ããšã³ããŠãã³ 275 ã¢ã»ãã¢ããããšã³ 275 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã
奜é©ã§ããã å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ275mgã®ããšã³ããŠãã³ãã
ã³çžä¹äœçšå€ãšããŠ275mgã®ã¢ã»ãã¢ããããšã³
ãåã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã
補é ããïŒ ïœ ããšã³ããŠãã³ 275 ã¢ã»ãã¢ããããšã³ 275 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ãã§ç²å€åãããç²å€ã也ç¥ãããŠå§çž®
ããŠé å€ãšããã ååç© ïŒ€ å®æœäŸ ïŒ äž»æŽ»æ§æåãšããŠ105mgã®ïŒïŒïŒâïŒâã¡ãã
ã·âαâã¡ãã«âïŒâããã¿ã¬ã³é ¢é žïŒïŒããã
ã»ã³ïŒããã³çžä¹äœçšå€ãšããŠ310mgã®ã¢ã»ãã¢
ããããšã³ãåã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«
ãã»ã«å€ã次ã®çµæãã補é ããïŒ ïœ ããããã»ã³ 105 ã¢ã»ãã¢ããããšã³ 310 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãæºããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯çã¿ã«èŠãã被æ€äœã«æäžã
ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã奜
é©ã§ããã å®æœäŸ ïŒ çµæäžã115ïœã®ãããªãŠã âïŒâã¡ããã·â
αâã¡ãã«âïŒâããã¿ã¬ã³ã¢ã»ããŒãïŒããã
ãã»ã³ãããªãŠã ïŒã䞻掻æ§æåãšããŠäœ¿çšã
350ïœã®ã¢ã»ãã¢ããããšã³ãçžä¹äœçšå€ãšããŠ
䜿çšããç¹ä»¥å€ã¯å®æœäŸïŒèšèŒã®åŠãã«ããŠããŒ
ã©ãã³ã«ãã»ã«ã補é ãããšãããããŠåã 115
mgã®ããããã»ã³ãããªãŠã ããã³350mgã®ã¢ã»
ãã¢ããããšã³ãå«æããã«ãã»ã«å€ãæäŸãã
ãã å®æœäŸ 10 䞻掻æ§æåãšããŠ115mgã®ããããã»ã³ããã³
çžä¹äœçšå€ãšããŠ350mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ããããã»ã³ 90 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ããçšããŠç²å€ãšãããç²å€ã也ç¥ãã
ãŠå§çž®ãé å€ãšããã ååç© ïŒ¥ å®æœäŸ 11 䞻掻æ§æåãšããŠ30mgã®ïœâãã³ãŸã€ã«ããã
ã¢ãããé žïŒã±ãããããšã³ïŒããã³çžä¹äœçšå€
ãšããŠ350mgã®ã¢ã»ãã¢ããããšã³ãåã å«æã
ã1000åã®ç¡¬ãŒã©ãã³ã«ãã»ã«å€ã次ã®çµæãã
補é ããïŒ ïœ ã±ãããããšã³ 30 ã¢ã»ãã¢ããããšã³ 350 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 æåã®åäžãªæ··åç©ã¯é åã«ãã€ãŠè¡ãªããïŒ
çåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯ãçã¿ã«èŠãã被æ€äœã«æäž
ããŠãæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®
ã奜é©ã§ããã å®æœäŸ 12 䞻掻æ§æåãšããŠ20mgã®ã±ãããããšã³ããã³
çžä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ã±ãããããšã³ 20 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ããçšããŠç²å€ãšãããç²å€ã也ç¥ãã
å§çž®ããŠé å€ãšããã ååç© ïŒŠ å®æœäŸ 13 䞻掻æ§æåãšããŠ85mgã®ïŒâïŒïŒïŒïŒâãžãã
ãâïŒâãªããœâ2Hâã€ãœã€ã³ããŒã«âïŒâã€
ã«ïŒâαâã¡ãã«ãã³ãŒã³é ¢é žïŒã€ã³ãããããš
ã³ïŒããã³çžä¹äœçšå€ãšããŠ280mgã®ã¢ã»ãã¢ã
ãããšã³ãåã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«ã
ã»ã«å€ã次ã®çµæãã補é ããïŒ ïœ ã€ã³ãããããšã³ 85 ã¢ã»ãã¢ããããšã³ 280 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åç©ãé åã«ãã€ãŠè£œé ãã
ïŒçåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯çã¿ã«èŠãã被æ€äœã«æäžã
ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã奜
é©ã§ããã å®æœäŸ 14 䞻掻æ§å€ãšããŠ35mgã®ã€ã³ãããããšã³ããã³
çžä¹äœçšå€ãšããŠ425mgã®ã¢ã»ãã¢ããããšã³ã
åã å«æãã1000åã®å§æœ°é å€ã次ã®çµæãã補
é ããïŒ ïœ ã€ã³ãããããšã³ 35 ã¢ã»ãã¢ããããšã³ 425 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ãã§ç²å€ãšãããç²å€ã也ç¥ããå§çž®ã
ãŠé å€ãšããã ååç© ïŒ§ å®æœäŸ 15 䞻掻æ§æåãšããŠ120mgã®Î±âã¡ãã«âïŒâã
ãšããã·ãã³ãŒã³é ¢é žïŒããšãããããšã³ïŒãã
ã³çžä¹äœçšå€ãšããŠ340mgã®ã¢ã»ãã¢ããããšã³
ãåã å«æãã1000åã®ç¡¬ãŒã©ãã³ã«ãã»ã«å€ã
次ã®çµæãã補é ããïŒ ïœ ããšãããããšã³ 120 ã¢ã»ãã¢ããããšã³ 340 ãã³ãã³ 250 ä¹³ç³ 750 ã¿ã«ã¯ 250 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 10 該æåã®åäžãªæ··åç©ãé åã«ãã€ãŠè£œé ãã
ïŒçåã®ç¡¬ãŒã©ãã³ã«ãã»ã«ãå ããã®ã«äœ¿çšã
ãã該ã«ãã»ã«å€ã¯çã¿ã«èŠãã被æ€äœã«æäžã
ãŠæºè¶³ãªé®çå¹æãæäŸããã®ã«äœ¿çšããã®ã奜
é©ã§ããã å®æœäŸ 16 䞻掻æ§æåãšããŠ100mgã®ããšãããããšã³ã
ãã³çžä¹äœçšå€ãšããŠ400mgã®ã¢ã»ãã¢ããããš
ã³ãåã å«æãã1000åã®å§æœ°é å€ã次ã®çµæã
ã補é ããïŒ ïœ ããšãããããšã³ 100 ã¢ã»ãã¢ããããšã³ 400 ãã³ãã³ 750 äºå¡©åºæ§ãªã³é žã«ã«ã·ãŠã æ°Žåç© 5000 ã¹ãã¢ãªã³é žã«ã«ã·ãŠã 2.5 埮ç²æ«ãšããæåãããæ··åãã10ïŒ ã®ãã³ã
ã³ããŒã¹ãã§ç²å€ãšãããç²å€ã也ç¥ããå§çž®ã
ãŠé å€ãšããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ (1) äž»èŠãªè©Šå€ãšã㊠ äžèšåŒ ãæããïŒâïŒïŒïŒïŒâãžã¯ããããšãã«ïŒ
ã¢ãããã³ãŒã³é ¢é žã  äžèšåŒ ãæããïŒïŒºïŒâïŒâãã«ãªãâïŒâã¡ãã«
âïŒâïœïŒ»ïŒâïŒã¡ãã«ã¹ã«ãã€ãã«ïŒâã
ãšãã«ïŒœâã¡ãã¬ã³ïœâ1Hâã€ã³ãã³âïŒ
âé ¢é žã  äžèšåŒ ã§è¡šããããïŒâïŒïŒâãããšããªã«ã«ã«ã
ãã«ïŒããããªã³é žã  äžèšåŒ ãæããïŒâã¡ããã·âαâã¡ãã«âïŒâã
ãã¿ã¬ã³é ¢é žã  äžèšåŒ ãæããïœâãã³ãŸã€ã«ãããã¢ãããé žã  äžèšåŒ ã§è¡šããããïŒâïŒïŒïŒïŒâãžãããâïŒâ
ãªããœâ2Hâã€ãœã€ã³ããŒã«âïŒâã€ã«ïŒ
âαâã¡ãã«ãã³ãŒã³é ¢é žã  äžèšåŒ ã§è¡šããããαâã¡ãã«âïŒâããšããã·ã
ã³ãŒã³é ¢é ž ãŸãã¯è©²ååç©ïŒ¡ïŒä¹è³ïŒ§ïŒã®äœããïŒã€
ã®ãç¡æ¯æ§ã®ãæ²»çåŠçã«åã容ããããå¡© ããæãäžçŸ€ããéžã°ããäžã€ã®ååç©ïŒãã
ã³ (2) çžä¹äœçšãããè©Šå€ãšããŠã¢ã»ãã¢ããããš
ã³ ãçµã¿åããŠææ害å容åšæ§ãå¹æçã§ããé
ã ãå«æããããã§è©²äž»èŠè©Šå€ããã³è©²çžä¹äœ
çšå€ãæ²»çåŠçã«åã容ããããæ äœãšã®æ··å
ç©äžã«ãããæçšåäœã®åœ¢ããããçã¿ãæã
ãã®ã«é©ããè¬å€çµæç©ã ïŒ æçšåäœã®åœ¢ãé å€ãŸãã¯ã«ãã»ã«ã§ããã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ æçšåäœãããã (1) çŽïŒä¹è³28mgã®ïŒâïŒïŒïŒïŒâãžã¯ããã
ãšãã«ïŒã¢ãããã³ãŒã³é ¢é žååç©ããã³ (2) çŽ110ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ ãå«æãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæ
ç©ã ïŒ äž»èŠãªææ害å容åšå€ããããªãŠã ïŒâ
ïŒïŒïŒïŒâãžã¯ããããšãã«ïŒã¢ãããã³ãŒã³
ã¢ã»ããŒãã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®
çµæç©ã ïŒ æçšåäœãããã (1) çŽïŒä¹è³100mgã®ïŒïŒºïŒâïŒâãã«ãªãâïŒ
âã¡ãã«âïŒâïœïŒ»ïŒâïŒã¡ãã«ã¹ã«ãã€ãã«ïŒ
ããšãã«ïŒœã¡ãã¬ã³ïœâ1Hâã€ã³ãã³âïŒâ
é ¢é žååç©ãŸãã¯ãã®å¡©ããã³ (2) çŽ65ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ ãå«æãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæ
ç©ã ïŒ äž»èŠãªæŽ»æ§å€ãïŒïŒºïŒâïŒâãã«ãªãâïŒâ
ã¡ãã«âïŒâïœïŒ»ïŒâïŒã¡ãã«ã¹ã«ãã€ãã«ïŒã
ãšãã«ïŒœã¡ãã¬ã³ïœâ1Hâã€ã³ãã³âïŒâé ¢é ž
ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ æçšåäœãããçŽ129ä¹è³430mgã®ïŒâïŒïŒâ
ãããšããªã«ã«ã«ããã«ïŒããããªã³é žååç©ã
ãã³çŽ113ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ãå«æ
ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ æçšåäœããã150ä¹è³400mgã®ïŒâïŒïŒâã
ããšããªã«ã«ã«ããã«ïŒããããªã³é žååç©ãã
ã³çŽ125ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãå«æã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒ æçšåäœãããçŽ85ä¹è³125mgã®ïŒâã¡ãã
ã·âαâã¡ãã«âïŒâããã¿ã¬ã³é ¢é žååç©ãã
ã³170ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ãå«æã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ äž»èŠãªææ害å容åšå€ãïŒïŒïŒâïŒâã¡ã
ãã·âαâã¡ãã«âïŒâããã¿ã¬ã³é ¢é žã§ããã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ æçšåäœãããçŽ12ä¹è³50mgã®ïœâãã³ãŸ
ã€ã«ãããã¢ãããé žååç©ããã³170ä¹è³450mg
ã®ã¢ã»ãã¢ããããšã³ãå«æãããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ äž»èŠãªæŽ»æ§å€ãïœâãã³ãŸã€ã«ãããã¢ã
ããé žã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæ
ç©ã ïŒïŒ æçšåäœãããçŽ25ä¹è³150mgã®ïŒâïŒïŒïŒ
ïŒâãžãããâïŒâãªããœâ2Hâã€ãœã€ã³ããŒ
ã«âïŒâã€ã«ïŒâαâã¡ãã«ãã³ãŒã³é ¢é žååç©
ããã³çŽ135ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ãå«
æãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ æçšåäœãããçŽ35ä¹è³130mgã®ïŒâïŒïŒïŒ
ïŒâãžãããâïŒâãªãã·â2Hâã€ãœã€ã³ããŒ
ã«âïŒâã€ã«ïŒâαâã¡ãã«ãã³ãŒã³é ¢é žååç©
ããã³çŽ150ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãå«
æãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ æçšåäœããã(1)çŽ84ä¹è³168mgã®Î±âã¡
ãã«âïŒâããšããã·ãã³ãŒã³é ¢é žååç©ããã³
(2)çŽ113ä¹è³450mgã®ã¢ã»ãã¢ããããšã³ãå«æã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã ïŒïŒ æçšåäœããã(1)çŽ90ä¹è³150mgã®Î±âã¡
ãã«âïŒâããšããã·ãã³ãŒã³é ¢é žååç©ããã³
(2)çŽ250ä¹è³425mgã®ã¢ã»ãã¢ããããšã³ãå«æã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®çµæç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/970,510 US4233314A (en) | 1978-12-18 | 1978-12-18 | Analgesic potentiation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5594318A JPS5594318A (en) | 1980-07-17 |
| JPH0140009B2 true JPH0140009B2 (ja) | 1989-08-24 |
Family
ID=25517059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16287979A Granted JPS5594318A (en) | 1978-12-18 | 1979-12-17 | Analgesic composition |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4233314A (ja) |
| JP (1) | JPS5594318A (ja) |
| ZA (1) | ZA796821B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4322427A (en) * | 1981-04-16 | 1982-03-30 | Bristol-Myers Company | Analgetic compositions and methods of use |
| DE3348444C2 (de) * | 1982-07-22 | 1995-02-02 | Richardson Vicks Inc | Analgetische und antiinflammatorische Mittel |
| JPS59501459A (ja) * | 1982-07-22 | 1984-08-16 | ãªãã€âããœã³âããã¯ã¹ïŒã€ã³ã³âãã¬ã€ãã€ã | ã«ãã§ã€ã³ãå«ãã§æãæ¹è¯ãããé®çåã³æçççµæç©äžŠã³ã«ãã®äœ¿çšæ¹æ³ |
| US4599359A (en) * | 1982-12-09 | 1986-07-08 | Stephen A. Cooper | Hydroxyzine-containing analgesic combinations |
| US4564614A (en) * | 1984-10-11 | 1986-01-14 | Pfizer Inc. | Antiinflammatory methods |
| US4812455A (en) * | 1984-10-11 | 1989-03-14 | Pfizer Inc. | Antiinflammatory compositions and methods |
| US4766117A (en) * | 1984-10-11 | 1988-08-23 | Pfizer Inc. | Antiinflammatory compositions and methods |
| US4672061A (en) * | 1985-01-28 | 1987-06-09 | Pfizer Inc. | Antiinflammatory compositions and methods |
| US4874757A (en) * | 1984-10-11 | 1989-10-17 | Pfizer Inc. | Antinflammatory compositions and methods |
| CH664085A5 (de) * | 1985-02-08 | 1988-02-15 | Ciba Geigy Ag | Pharmazeutische praeparate mit analgetischer wirksamkeit, sowie deren herstellung. |
| LT3086793T (lt) | 2013-12-24 | 2022-08-25 | Virginia Commonwealth University | Deguonimi įsodrintų cholesterolio sulfatų (ocs) naudojimas inkstų disfunkcijai gydyti |
-
1978
- 1978-12-18 US US05/970,510 patent/US4233314A/en not_active Expired - Lifetime
-
1979
- 1979-12-14 ZA ZA00796821A patent/ZA796821B/xx unknown
- 1979-12-17 JP JP16287979A patent/JPS5594318A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5594318A (en) | 1980-07-17 |
| US4233314A (en) | 1980-11-11 |
| ZA796821B (en) | 1981-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4066756A (en) | Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin | |
| US4556678A (en) | Sustained release propranolol tablet | |
| RU2198655C2 (ru) | ÐПЌбОМОÑПваММÑй пÑепаÑаÑ, ÑПЎеÑжаÑОй 4-(ÑÑОÑÑПÑЌеÑОл)аМОлОЎ 5-ЌеÑОлОзПкÑазПл-4-каÑбПМПвПй кОÑлПÑÑ Ðž n-(4-ÑÑОÑÑПÑЌеÑОлÑеМОл)аЌОЎ 2-ÑОаМП-3-гОЎÑПкÑОкÑПÑПМПвПй кОÑлПÑÑ | |
| UA76417C2 (en) | Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol | |
| KR100202154B1 (ko) | íëŒìží몰 ë° ëí늬ëì íšì í íëŠ íŒë³µ ì ì | |
| US4234601A (en) | Analgesic potentiation | |
| US4207340A (en) | Analgesic potentiation | |
| JPH0140009B2 (ja) | ||
| US4233316A (en) | Analgesic potentiation | |
| US4233317A (en) | Analgesic potentiation | |
| JPS6357405B2 (ja) | ||
| US4233315A (en) | Analgesic potentiation | |
| HU222888B1 (hu) | Anilid vegyÃŒletek alkalmazása I tÃpusú allergiás betegségek megelÅzésére és kezelésére alkalmas gyógyszerkészÃtmények elÅállÃtására | |
| AU666992B2 (en) | Pharmaceutical composition for preventing or treating arteriosclerosis | |
| EP0012621B1 (en) | Analgesic composition comprising acetaminophen as a potentiating agent | |
| US4242353A (en) | Analgesic potentiation | |
| CA1307739C (en) | Anti-inflammatory compositions | |
| JP3982889B2 (ja) | ã€ããããã§ã³å«æå»è¬è£œå€ | |
| JP2000344665A (ja) | é®çå€ | |
| WO2000021534A1 (en) | Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine | |
| JPH09227371A (ja) | ç²¥ç¶åè硬åæå¶å€ | |
| RU2445091C1 (ru) | ЀаÑЌаÑевÑОÑеÑÐºÐ°Ñ ÐºÐŸÐŒÐ¿ÐŸÐ·ÐžÑÐžÑ Ð² вОЎе ÑвеÑЎПй лекаÑÑÑвеММПй ÑПÑÐŒÑ Ðž ÑпПÑПб ее пПлÑÑÐµÐœÐžÑ | |
| JP2007137896A (ja) | ã€ããããã§ã³å«æå»è¬è£œå€ | |
| IE43955B1 (en) | Pharmaceutical composition and dosage units thereof | |
| US4031213A (en) | Pharmaceutical composition and method for the treatment of hydropic conditions |